

INDEX AND GLOSSARY

● The small letter "e" before a page-number identifies the page where the term is explained or defined.
Example: e275

● The rows farthest to the left in this Index are alphabetized on the basis of letters exclusively. Spaces, hyphens, other punctuation marks, and numbers are treated as if they were absent.

● If a part of our text is hard to find again, it may be findable as a sub-entry under some of the big entries, such as:

A-Bomb Survivor Study
 AHA (American Heart Association)
 Atherosclerosis
 Atherosclerotic lesions
 BEIR reports
 Cancer etiology
 Causation: Types of evidence
 Chromosome
 Co-action, among causes of Cancer & IHD
 Databases: Protective measures against bias
 Delivery-times of cases, post-irradiation
 "Demands an explanation"
 Dietary approaches to prevention & therapy of IHD
 Dose, ionizing radiation
 Dose-levels from some current xray procedures
 Dose-rate
 Dose-reduction, achievements & opportunities
 Dose response
 Dose-units of ionizing radiation
 Endothelial cells of vessels
 Fibrous cap of atherosclerotic plaque
 Fluoroscopy
 Ionizing radiation
 Latency periods
 Matching
 MortRate
 Multi-step model of carcinogenesis
 Mutations
 Per capita population dose from medical radn
 PhysPop
 Pitfalls in epidemiology
 Plasma lipoproteins: Basic data
 Plasma lipoproteins: Lipid Hypothesis
 Plasma lipoproteins: Some current controversies
 Prospective studies
 Repair system of cell for genetic damage
 Risk per rad
 "Smoking guns"
 Smooth muscle cells of arteries
 Track (ionization)
 Triglyceride
 Unified Model of Atherogenesis & Acute IHD Death
 UNSCEAR reports
 Xrays
 Xrays: History 1896-1960 of medical usage
 Xrays: History 1960-1999 of medical usage

A

* indicates multiplication.
 ^ indicates that the next number is an exponent.
 Abbott (R.D.) 1984: Triglycerides & IHD risk, 566
 Abelson (Philip) 1994: He claims hazard of low-dose radn is overestimated, 528. Pls see: Free radical.
 A-Bomb Survivor Study, e41-e42
 Really a LOW-dose study, 42, 46, 48
 Dose & age-distribution of participants, 42
 Bomb-rads converted to medical rads, 48
 Latency intervals: By 1950, cancer-rates rising in exposed population, 92. Of all the radn-induced solid cancers, 22% occurred 40-45 years after the bombing, 49, 357
 Study far from completed, 49
 Its evidence suggests no threshold-dose, 43, 46
 Shape of dose-response, solid cancers, 42-43
 Findings on female genital cancers, 162
 Gamma-induced benign tumors, 297
 Marginal results for IHD, 501-502
 Chronic retroactive changes described, 43-44, 54
 Solution proposed & demonstrated, 44
 Access of xrays to every gene of every cell 8, 40, 343, 536. Other mutagens may lack universal access or activity, 377, 497
 Accumulated mutations. Please see: Mutations.
 Accumulated per-capita pop'n dose. Pls see: PhysPop.
 Acquired mutations (post-conception), e92, e342
 ACS = American Cancer Soc. Described in Ref. List.
 ACS role in early smoking-health inquiry, 361
 Heath (C.W.), view of xray-role in breast canc, 500
 ACS 1992: Advice to avoid fluoroscopy, 41
 ACS-CA 1992: Cancer MortRates 1930-1940, 210, 505
 ACS-CA 1997: Mortality statistics 1993, 276, 278
 Acute exposure (all at once), e223
 Acute IHD events, e276, e318, e347
 Acute radiation syndrome, e520
 Adam (Ervin) 1987: Viral etiology, atheroscl, 307, 308
 Adaptive responses of cells to radn, 527, 617
 Adjusted data (for matching), e82, e367
 Such values are always approximations, 381
 Hazard of layers of adjustments, 15, 569
 Smoking adjustment for post-1940 years, 378-381
 We show "before" and "after" values, 367

- Adler (Yolanda T.) 1986: Unfavorable review of Gofman/O'Connor Xray book, 51
- Adventitia (artery's outer coat), e299
- Advocacy reduces scientific credibility? 19-20
- Age:
- Many xray exams occur below age-45, 20, 37
 - Age and radiation-sensitivity, 20, 37
 - Age and accumulation of chromosome mutations, 39
 - Age-adjusted MortRates, defined in Grove 1968, e83
 - Know which reference year is used, 82
 - Role in "matching" the 9 Census Divisions, 82, 83
 - Sample calculations, age-adju MortRates, 87, 88, 503
 - Age-distribution, 1990 canc MortRate, 32, 84, 88, 356
 - Age-specific MortRates, e83-84, e498
 - Age-specific All-Cancer MortRates (1990), 88
 - Age-specific All-Cancer MortRates (1900-1990), 504
 - Age-specific Breast Cancer MortRates (1950-1990), 88
- AHA = American Heart Assn. Described in Ref. List.
- Defines types of atherosclerotic lesions, 301
 - Awards the Lyman Duff Memorial Lectureship, viii, 303, 314, 577
 - Age-adjusts MortRates to 1940 reference year, 82
 - AHA role in early smoking-health inquiry, 361
 - AHA 1995: Congenital heart defects, 37, 278
 - Annual rates of diseases of the heart, 277-278
 - No symptoms before 48% of fatal heart attacks, 324
 - Big progress in controlling hypertension, 287, 350
 - AHA 1996: Diagnostic cardiac catheterizations, 37
- Ahfeldt (P-E.), co-author, Carlson 1979, 565
- Ahmed (A.J.) 1990: Tumor hypothesis, plaque, 330
- Ahrens (Edward) 1955: Diet & blood lipids, 560
- AICR = American Institute of Cancer Research.
- 1997: Estimates ~ 35 % of cancer due to diet, 495
- Alaska omitted, 57, 78, 79, 80
- Albert (R.E.) 1977: Atheroscl plaques induced in cockerels by carcinogens, 330
- Albumin: Much smaller in size than lipoproteins, 333
- Alfthan (G.) 1994: Homocysteine & IHD etiology, 331
- All-Cancers-Combined, e107
- Age-adju MortRates by Census Divisions, Chaps 6 & 7
 - Mid-century dose-response with PhysPop, 12-13, 24
 - Age-adju & age-specific National MortRates, 504
- Alpha lipoproteins, 311, 312, 538
- Alpha radiation, e517
- A "high-LET" radn, e47. Experimental demo: A single alpha particle can induce mutation, 529
 - Alpha radn: Smoke's primary atherogen? 329
 - Alpha radn: Smoke's primary lung-carcinogen? 362
- AMA = American Medical Assn. Described in Ref. List.
- AMA 1950: Registry of U.S. Physicians, 58
 - AMA 1965: Distribution of U.S. Physicians: Ref List.
 - AMA 1982: PhysPop data, 58
 - AMA 1986: PhysPop data, 58
 - AMA 1990: PhysPop data, 75
 - AMA 1993: Categories of physicians, 57, 58, 70
 - AMA 1994: Physpop data, 58, 75
- Ambrose (J.A.) 1986+1988: Degrees of stenosis, 322
- American Cancer Society. Please see: ACS.
- American Heart Assn. Please see: AHA.
- American Roentgen Ray Society, 27, 29, 609
- Ames (Bruce N.) 1989+1995: Rate of endogenous DNA damage, 528, 531, 532
- Amromin (G.D.) 1964: Co-action between high-dose x-radiation and cholesterol-feeding, 604
- Anderson (K.) 1985: How to cut xray dose, 23
- Anderson (Robert E.) 1989: Autopsy data, canc, 81
- Anderson (T.J.) 1995: IHD therapy, prevention, 345
- Andrus (Prof. E. Cowles): Served well as a neutral in arguments which occurred, 545
- Anesthesia, and sudden death, 28
- Aneuploidy (wrong number of chromosomes), e533, e534
- Angina pectoris, e276
- Angio. Relating to a vessel, usually a blood vessel.
- Angiogenesis, e300. Research on its stimulation (IHD), 300. Research on its suppression (cancer) 536
- Angiography = an xray examination (including fluoroscopy) of the blood vessels, 34, 303
- Angioplasty = a medical procedure to increase the interior diameter of a stenotic artery by inflating a balloon on the tip of a catheter. Re-stenosis may occur. Associated xray dose, 36, 600
- Anitschkow (N.) 1933: World-famous research on "rabbit atherosclerosis" induced by cholesterol-feeding, 317, 538
- Antonis (A.) 1961: Diet & serum triglycerides, 560
- Apoptosis (enzyme-regulated cell-death), e340, 377
- Apple (Raymond) 1994+1995: Inherited vulnerability to cervical cancer, 164-165
- Approximation is inherent in adjusted data, 381
- Arbeit (J.) 1996: Co-action in cervical canc, 165
- Armstrong (M.L.) 1989: Plaque obstructs lumen only late in its growth, 303
- Arnesen (E.) 1995: Serum homocysteine & IHD, 331
- Arrhythmia, e276
- Arteriosclerotic Heart Disease, e275.
- Artom (C.) 1965: Co-action, radn & cholesterol, 605
- Aspirin & heart attacks, 352, 567
- Astonishment when strong, positive PhysPop-IHD correlation was uncovered, 13, 16, 233
- Atherosclerosis, e275, 299, e301-e303
- Develops over years, decades, 300, 349, 595
 - Controversy over what starts the process, 300, 305
 - "Schools" of thought on etiology, Chaps 44 + 45
 - Non-radn non-lipid risk-factors, 332, 337, 349-351
 - Independent atherogens vs. markers, 306, 543-544, 552-554, 565-566, 577-585, 586
 - Atheroscl as precursor to stroke, gangrene too, 307
- Atherosclerotic lesions, described: 300-304, 323, 339-341. Formal "types," e301, e348-e349.
- The adjacent tissue is healthy, 300, 301, 302, 338, 339, 349
 - Lesions initially grow away from lumen, 303, 322
 - Thrombogenic lipid core, 323
 - Plaque is "hive of activity," 339, 347
 - Unpredictable path of evolving lesions, 321, 348-349
 - Progression of lesions. Please see: Progression.
 - High-dose radn causes vessel-and-heart damage which differs from athero lesions 1, 9, 16, 275, 599-608

Atomic Energy Commission: Its 1940-1950 radn experts were transferred from medical world, 31
 AEC alarmed by analysis in Gofman 1969-b, viii, 533
 Autopsy observations. Cancer & general, 81-82
 Lesions of the heart & vessels, 301, 600-606
 Failure to fund autopsies in clinical trials, 82
 Autopsy rates & PhysPop-cancer dose-response, 510
 Avins (Andrew L.) 1989+1997: Are high serum tri-glyceride levels an indep risk factor for IHD? 316
 "Awe, humility, and gratitude" (for gene-repair), 524

B

Babies fluoroscoped during check-ups, 29, 31, 610
 "Background" canc-rate includes xray-cases, 50, 91
 Background radn, e520. Pls see: Natural background.
 Bacterial infections. As atherogens, 309-310.
 As carcinogens, 210, 435.
 Baermann (G.) 1904: Radiation injures vessels, 607
 Bailar (J.C.) 1997: Age-adjusting to 1990, 82
 Barter (P.) 1995: Pravastatin Study & breast ca, 320
 Baverstock (Keith) 1981+1983+1987: Radium dials, 524
 1991: Response to Billen 1990, 524
 1992: Latency<5yr, Chernobyl-induced thyroid ca, 91
 BEIR.
 Biological Effects of Ionizing Radiation (a govt-sponsored Com'tee at US Natl Academy of Sci), e114
 BEIR 1972 (BEIR-1): Latency < 5yr for bomb-induced leukemia, 91. Mutagenicity (RBE) of radns, 518
 BEIR 1980 (BEIR-3 Report):
 Cancer is major effect of ionizing radn, 11, 40
 Hiroshima & Nagasaki autopsy data, re cancer, 81
 BEIR 1990 (BEIR-5 Report):
 Cig-smoke irradiates bronchial epithelium, 362
 Co-actors modify radn's potency/rad, 114, 376-77
 Comtee cannot explain big variation risk/rad, 48
 Comtee says "legitimate" questions exist because some low-dose studies produce risk-estimates "substantially" higher than BEIR-1990's own, 11
 Radn induces benign tumors as well as cancer, 297
 Xrays more potent than bomb radn, 46
 BEIR 1999 (BEIR-6 Report): Co-actors, 4.
 Co-actors modify radn's potency/rad, 114, 377
 Fractional causation, 4
 Bell (F.P.) 1974a+b: How do lipids enter intima? 318
 Benditt (Earl P.), pathologist, Univ. Washington.
 1973+1974+1976+1977+1988: Monoclonal hypothesis of atherosclerosis, 1, 6, 16, 325-327, 339, 350
 "Benign smooth muscle tumor," 327
 Comments by others, 328-331
 1976: Description of atherosclerotic lesions, 301
 1988: Some wise words about research, 352
 Benefit-risk of dose-cutting: All benefit, no risk, 18
 Benefits of lipid-lowering, 318-321, 322, 345-346, 353
 And endothelial function, 345
 Add'l entry: Stabilization of plaque.
 Benefits of medical radn, 9, 17, 19, 91, 234, 515
 Benign tumors, radiation-inducible, 297
 Bennett (H.S.) 1956: How do lipids enter intima? 317
 Best estimate, central value, e95. Most likely value, 217, 283

Best-fit equation, e63
 Best-fit line, e63. Add'l entry: Steepness.
 Beta lipoproteins, 311, 312, 538
 Beta radiation, beta particle, e517. And 44, 47, 329
 High-energy betas less mutagenic than xrays, 9
 Low-energy tritium is very mutagenic, 47
 Beutler (E.) 1962: On enzymes in mosaicism, 326
 "Beyond a reasonable doubt," 213, 272, 367, 513
 Bias-free databases used by this monograph, 14, 52, 55, 111, 216, 283, 295, 501
 Add'l entry: Databases, protective measures ag bias
 "Bickering (unnecessary) to no good end," 608
 Bierman (Edwin L.), 350
 1976: Smooth muscle cells & LDL, 327
 1992: About 75% of diabetics die of IHD, 247
 1992: Role of plasma triglycerides in atheroscl, 316
 Bihari-Varga (M.) 1967: Lipid retention, intima, 318
 Billen (Daniel) 1990+1991: On endogenous free radicals, 528. Proposes an equivalence between endogenous metabolic free radicals and free radicals induced by ionizing radn; then argues that low-dose radn is a negligible hazard, 530-532
 Demonstrated fallacy of free-radical argument, 531-2
 Biologically unnatural energy (transferred by ionizing radiation to molecules), 8, 38, 532
 Biopsies which are xray guided, 35
 Bishop (Louis) 1922: Fluoroscopy, widespread use, 29
 Bittl (John H.) 1996, NEJM review article:
 Endorses intense effort to lower lipid levels, 319
 How lipid-lowering achieves its benefit, 345
 Moderate stenosis and acute IHD events, 322
 Bjorkerud (S.) 1971: Injury, intimal endothelium, 306
 Black (A.) 1975: Intense exertion & acute IHD, 324
 Black's Crack in the Plaque (plaque rupture), 324
 Blanchard (R.L.) 1967: Alpha radn in cig. smoke, 362
 Blankenhorn (David H.), 1992 Lyman Duff Award, 303.
 1987: CLAS Study on Colestipol Niacin Therapy, 336
 1993: MARS, Monitored Atheroscl Regression, 336
 1994: Lyman Duff Memorial Lecture, 303-304, 316, 321, 322, 325, 347 (progression)
 Problem in detecting progression, regression, 303-4
 Blatz (Hanson) 1970: Mid-century well-baby exams used fluoroscopy for first 2 yrs of life, 29
 Boice (J.D., Jr.) 1977+1978+1981+1991: Breast-cancer effect of serial low-dose fluoroscopies, 523
 Bomb-rads: Conversion to medical-rads, 47
 "Bombs" or violent energy-deposits by radn, 8, 38, 517
 Bond (V.P.) 1978: Xrays more damaging than gammas, 47
 Bone-marrow dose, 34
 Borek (C.) 1983: Xrays more damaging than gammas, 47
 Bosch (F.X.) 1995: Cervical canc & HPV infect'n 164-65
 Bottinger (L.A.), co-author, Carlson 1979, 565
 Boveri (Theodor) 1914: A scientist far ahead of his time who suggested chromosomal abnormality as a cause of human cancer, 533
 Boxy symbols of graphs, e92, e95, e110. How to know which box is which Census Div, 110. Sample, 220-221
 Boyer (Herbert) 1996: Over-analysis, before starting a project, can cause paralysis, 55

Braestrup (Carl B.), physicist, New York hospitals.
 1942: Fluoroscopic over-exposures, 29-30, 612
 1969: Limit set at 100 roentgens/exam, 30
 Bragdon (J.M.) 1956: Composition of lipoproteins, 333
 Braunwald (Eugene) 1997 in NEJM Shattuck Lecture:
 Half of IHD cases have no established risk, 337
 Breast cancer.
 Age-adjusted MortRates flat over time, vs. rising
 incidence, 423, 506
 Age-specific MortRates USA, 88, 423
 And dietary fat, 569
 And pravastatin, 320
 Current share of Breast Canc due to medical xrays:
 75% (from Gofman 1995/96), 5, 52, 125, 500, 501
 83% (from this monograph), 423, 501
 1% (from Evans 1986), 500, 501
 Reasons for the Gofman-Evans disparity, 500-501
 Serial low-dose fluoroscopy & Breast Cancer, 28,
 48, 501, 523-524. Breast Cancer provides much
 evidence on low-dose radiation carcinogenesis, 51
 Brenner (D.J.) 1989: Low energy xrays=extra damage, 47
 Brensike, (J.F.) 1984: IHD therapy, prevention, 336
 Brewen, (J.G.) 1973: Chromosome breakage by radn, 38
 Bronchitis (chronic) and smoking, 362
 Brosius (F.C. III) 1981: Heart damage by radn, 605
 Brown (B. Greg) 1986+1989+1990+1993: Etiology of
 atheroscl & acute events, 318, 321, 322, 323, 325,
 336, 345, 347-348
 Characteristics of rupture-prone plaques, 323
 Less stenotic lesions more numerous, perilous 347-48
 Plaque stabilization, 318, 345
 Buchwald (H.) 1990: IHD therapy, prevention, 336
 Bucky (Gustav) 1927: 'Grenz' (soft) xrays, 30-31
 Budowski (P.) 1985: n-3 vs. n-6 fatty acids, 569
 Buja (L.M.) 1994: Stabilization of plaques, 325
 Burke (Allen P.) on plaque rupture and erosion:
 1998: Plaque erosion & sudden death in women, 321
 1999: Plaque rupture, exercise vs. rest, 321, 324
 Burney (Leroy E.), 1957 warning about smoking, 361
 Burr (M.L.) 1989, DART Study: Fish, fish oils 568, 569
 Burton (E.C.) 1998: Autopsy and canc. diagnosis, 82
 Buschke (Franz) 1942: Well-baby fluoroscopy: 610, 612
 Est. dose = 100 R during first year of life, 29
 Concern over causing inherited afflictions, 31

C

CAD = Coronary Artery Disease, e7, e275
 Calcium deposits in atheroscl plaque: 34, 303, 304,
 305, 329, 347. Detection by fast CT scans, 34
 Calcium deposition in other lesion-types too, 329
 Campbell (Gordon R.) 1988, Smooth muscle cells are
 multi-functional, 306
 Cancer deaths (USA, 1993) = 529,904 (23.4%), 276, 278
 Cancer etiology: Why cancer called 100 diseases, 535
 Ionizing radn is an undisputed cause, 2, 7, 40-41,
 521-529. Pre-xray etiology, 10, 209, 210.
 Single-cell origin of malignancy, 325, 526, 529, 534
 Initiation-promotion model, 3, 114, 330, 376, 526
 Multi-mutation model, 3, 526
 Inherited predisposition, 3, 51, 164-165, 495, 496
 Add'l entries: Co-action. Infections. Mutation.

Cancer MortRates:
 Some types rise while others fall, 210, 496-497
 Add'l entries: All-Cancers-Combined. MortRates.
 "Carbohydrate effect" on plasma lipoproteins, 315, 316,
 e560, 564, 573
 High carbohydrate diets, not always healthy, 311,
 315, 555, 560, 573
 Low carbohydrate therapy, 560, 561, 574, 575
 Carcinogenesis. Please see: Cancer, etiology.
 Cardiac arrest, e276
 Cardiac catheterizations, 37. Multiple, 600
 Cardiovascular Diseases (CVD), e276-e278. Trends, 287
 Carlson (L.A.) 1979: Serum triglyceride as predictor
 of heart attack rate, 565
 Caro (C.) 1971: Injury of arterial endothelium, 307
 Cashin-Hemphill (L.) 1990, CLAS II: IHD therapy, 336
 Castelli (William P.) 1986: Framingham Study, 546-547,
 565-566
 Dose-response shown between entry-level Sf 0-20
 cholesterol-rich lipoproteins & IHD, 546-547
 Dose-response shown between entry-level of Sf 20-
 400 triglyceride-rich lipoproteins & IHD, 546, 565
 "Individuals who have high triglyceride levels
 should be considered at high risk for CHD," 566
 Cathcart (M.K.) 1985: Oxidized LDL & endothelium, 307
 Catheters: Placement guided by xrays, 9, 35, 37
 Multiple cardiac catheterizations & xray dose, 600
 Causation: Types of evidence.
 Evidence that putative cause precedes effect:
 1921 PhysPops predict 1940 Canc MortRates, 213-14
 1931 PhysPops predict 1950 IHD MortRates, 296, 513
 Does Chlamydia infection precede plaque? 310
 Elevated plasma lipoproteins precede infarct,
 544-547, 580
 Positive dose-response is presumptively causal,
 55, 296, 513, 514. "Gold standard," 213, 513.
 Correlation alone is not proof of causation, 213,
 272, 513, 514
 Example: Correlated Canc-IHD MortRates, 642-644
 Correlation PLUS add'l info & logic, 272, 295, 513
 "Beyond a reasonable doubt," 213, 272, 513
 Determination that an agent makes an independent
 contribution to the effect, and is not just
 correlated with the real causal agents ("Not easy
 to do," 544). Examples. C-reactive protein, 306.
 Chlamydia, 310. Sf 20-400, 316. Hyperinsulin-
 emia, 350-351. Sf 20-100, 543-544. HDL as anti-
 atherogen, 577-585. "Small dense LDL," 586-593.
 Clinical intervention trials, 309, 318-320, 332
 Examination: Any alternative, equally reasonable
 explanation? 15, 112, 507-512, 642-644
 Celermajer (D.S.) 1998: MRI may be capable of
 identifying rupture-prone plaques, 323
 Cell division: Distribution of chromosomes, 39
 Cells not always killed by mutation, 8, 39
 Cells per gram of tissue, 39, 44, 518, 529
 Cell-traversals required to deliver one rad, 47
 Census Bureau 1951+1959, populations for PhysPop, 58
 Census Divisions: Distribution of the states, 57
 Populations sizes of the Divisions, 1910-1990, 75
 Stability of PhysPop ranking by Divs, 61, 66

- Centers for Disease Control (CDC), 79
- "Central Dogma" about stenosis is re-examined, 322
And general wisdom about role of smooth muscle cells in atherosclerosis is challenged too, 323-324
- Central value, e95
- Cervical cancer and co-actors, 164-165. Smoking, 165
- cGy (centi-gray), e517. One rad.
- Chambers (R.) 1947: How do lipids enter intima? 317
- Chang (C-c.), co-author of Trosko 1980, 329, 350
- Chemotherapy for cancer: Slow beginning - 1943, 509
- Cheng (G.C.) 1993: Stress on fibrous cap, 323
- Cheng (Keith. C.) 1993: Genomic instability, 533, 534
- Chernobyl-induced thyroid cancer within 5 years, 91
- Chesebro (J.H.) 1992: Anti-thrombotic agents, 352
- Chest x-rays: Dose now ~100-fold lower than 1950, 34
- Chlamydia pneumoniae & IHD, 309-310
- Cholesterol, e562. Endogenous & dietary, 314, 538
- Cholesterol-rich lipoproteins, e313, e333, e550
- "Total cholesterol" measurement is not fully informative, 316, 556, 561
- Hypercholesterolemia: Synergism with radiation in rabbits, rats, pigeons, 604-605
- Deposition & removal of cholesterol from plaque, 578
- Cholesterol & Recurrent Events Study, 320-321
- Chromosome, e537. Accurate count, in 1956, 533
- Distribution during cell-division, 39, 533, 537
- Chromosomal mutations from radn, 5, 7, 38, 39
- Types of structural re-arrangements, 39, 533
- Accumulation with advancing age, 39
- Very low doubling dose, 5, 7, 9, e39, 343, 515
- Dose-response detectable 45 years later, 50
- Enzyme-guided breaks vs. messy radn breaks, 39
- Chromo "instability." Pls see: Genomic instability
- Chylomicron, e312, e333
- Ciampricotti (R.) 1989: Heart attacks, soon after vigorous exercise, 324
- Cigarette smoking: Annual rates, 1900-1994, 363, 371
- Gender-difference in smoking behavior, 364-365
- Recognized as carcinogen & IHD risk-factor, 361-362
- Role of alpha-radn? 329 (IHD), 362, 536 (cancer).
- Implicated in non-Respiratory-System cancer 165, 411
- Named as co-actor in cancer (BEIR), 114, 376
- Evidence that smoking-intensity was NOT alike across the Nine Census Divisions, and was inversely correlated with PhysPop, 366-367, 369
- Cigar-smoking: Approx as risky as cigarettes, 363
- Circumstantial evidence, 213, 272, 295, 513
- Cirrhosis of the liver, 81
- Clarke (M.) 1995: Unclear benefit of radiotherapy for breast cancer, 509
- Clarkson (T.B.) 1994: Plaque obstructs lumen only late in its growth, 303
- Clone, e325, e339
- Clones (dysfunctional) of non-SMCs possible too, 339
- Co-action, among causes of cancer & IHD, e3, 495
- Necessary co-actors, e3, e4, e98, e114, e283, e362, e376, e495
- Multiple co-actors per case of disease, 3, 4, 98
- Implication for preventing diseases, 4, 283
- Relation of co-action with Fractional Causation, e4
- Please see next column.
- Co-action continues:
- Carcinogenic co-actors alter each other's potency, 4, 90, 98, 114, 376-377, 441, 497, 623
- How: 377, 497
- List: Cancer co-actors w. radn, from BEIR, UNSCEAR, 114, 377. Co-actors in cervical ca, 164-165.
- Co-action, smoking and radon, 4
- Co-action, xrays and dietary cholesterol, 604, 605
- Add'l entries: Cancer, etiology. Multi-step model.
- Cobalt-60 and track-analysis, 525-526
- Cohen (M.) 1985: How to cut xray dose, 23
- Cohn (Edwin J.) 1946: Alpha & beta lipoproteins, 311
- Cohn (K.E.), co-author of Stewart 1967, 601
- Colditz (Graham): AAAS Breast Cancer Symposium, 51
- Collateral vessels, e300. And silent occlusions, 349
- Collimation of xray beam, 30, 34, fluoroscopy 36, 610
- Comments of note: About hesitation (Herb Boyer), 55
- On common obstacle to progress (Orville Wright), 515
- About progress in research (Earl Benditt), 352
- ComPrinci 1978: IHD therapy, prevention, 336
- Computed tomography. Please see: CT scans.
- "Concrete": MortRates set in concrete by PhysPop, 212
- Confidence limits on an estimate, e95
- C.L. on est. Fractional Causation, 14, 112-113, 116
- Confounding variables. Please see: Matching.
- Connective tissue = extracellular matrix, 340
- Connor (Sonja L.), co-author of Connor 1997, 555
- Connor (William E.), on diet and IHD, 556
- 1986: Metabolic effects of n-3 fatty acids, 563
- 1997: Exasperated by contradictory advice, 555
- Consensus 1985: IHD therapy, prevention, 336
- Constant-cohort, dual-dosimetry analysis, e44
- Constant, in linear regression, 14, e64, e94-95, e111. Add'l entry: Negative Constants.
- Control groups, 91, 618, 619. Placebo, 319-320
- Cook (Linda S.) 1997: Genital talcum powder: Users have higher risk of ovarian cancer, 164
- USA: 28 to 51% of women use it, 164
- Co-op 1956: First prospective study of certain serum lipoproteins, cholesterol, and IHD, 541, 545-546
- Coresh (Josef) 1996, and Peter Kuiterovich in JAMA on "Small, Dense LDL Particles and CHD Risk," 586
- Coronary arteries, e299
- Correlation, perfect & linear, e63, e92
- Correlation and causation. Please see: Causation.
- Correlation can persist while x and y variables change in opposite directions, 97-98
- Correlation axiom for radn-induced cancer, e99
- Cotran (Ramzi S.), co-author of Munro 1988, 302
- Courtice (F.C.) 1962: Transfer-rate of lipoproteins across capillary wall varies with size, 317
- Cox (Roger): NRPB rejects threshold, 527
- Cralley (L.J.) 1968: Asbestos in talcum powder, 163
- Cramer (D.W.) 1982: Talc, asbestos, and elevated rate of ovarian cancer, 163-164
- Credibility in science: Reduced by advocacy? 19
- Ruined by discarding barriers against bias, 43, 54
- Undermined by conflict-of-interest, 54-55
- Crete: Heart-healthy diet, 566
- cSv (centi-sievert), e518. One rem.

CT scans: Dose level per exam rising, 34
 Frequent organ-dosage per exam: 1-5 rads, 49
 35% of CT exams received below age 45, 37
 Ultra-fast CT scans detect athero calcium deposit 34
 "Culprit" plaques (the ones causing acute events), 347
 Cumulative effect of radn, 9. Please see: Mutation.
 Cuzick (J.) 1994: Radiotherapy for breast cancer and
 cardiac-related deaths, 508-509
 CVD = CardioVascular Diseases, e276-278
 CytoMegalovirus (CMV) and IHD, 307, 308

D

Danesh (J.) 1997: Infections & vascular disease, 310
 Daoud (A.S.) 1963: Plaque rupture & heart attack, 324
 Databases: Protective measures against bias.
 Some well-established barriers to bias, 43
 First obligation of analysts, 14, 216
 Einstein would be misled, 216
 Peril from "fiddlers," 43-44, 546
 Potential for tainted databases, 54-55, 216, 295
 Status should be "above suspicion," 44
 Davidson (M.) 1998: Infection and IHD, 309
 Davidson (R.G.) 1963: Mosaicism, inactive genes, 325
 Davies (M.J.) 1985+1990: Plaque rupture, 321, 322
 Davis (Devra Lee): AAAS Breast Cancer Symposium, 51
 Dawber (Thomas R.), Framingham Heart Study: In 1965,
 he provided list of de novo cases of IHD in 4,509
 entrants whose lipoproteins were measured by Donner
 Lab 12 years earlier, 546, 579
 Deaths, USA, 1993: 15 Leading Causes, 278
 DeBakey (Michael E.): Viral etiology, atheroscl, 307
 Defense Department: Depended on medical professionals
 for advice on radn, 31
 DeLalla (Oliver F.), valued member, Donner group, 315
 1954-a: Ultracentrifugal techniques, 541, 557, 558
 1954-b: High-density lipoproteins, 312, 587
 1958: Livermore Lipoprotein Study, 547, 577
 1961: Lipoprotein inter-correlations, 544, 577
 Deletions, e39, e534. Radn-induced, 5, 7, 38-39
 Delivery time of cases, post-irradiation, e49
 Build-up due to gradual deliv'y 89-90, 101, 210, 499
 Equilibrium of production & delivery rates, 90, 101
 Build-down after reducing radn dose, 90-91, 101, 356
 Cancer MortRates are affected by radn-exposures
 decades earlier, 32, 52, 108, 212, 356
 Please see: Latency periods.
 DeLorgeril (Michel) 1994-b: Inflammation, athero, 325
 DeLorgeril (Michel) 1994+1996+1997+1998+1999, Lyon
 Diet Heart Study (Mediterranean Diet): 556, 566-569
 Possible reasons for its benefits, 568-569
 "Demands an explanation," 13, 15, 234, 272, 337,
 343, 355, 512, 514, 644
 Dental xrays, 30, 31, 610
 USA: Estimated 100 million exams per year, 11
 Dependent variable, in dose-response, 11
 Despres (J-P.) 1996: Hyperinsulinemia and IHD, 351
 Dewing, (Stephen B.) 1969: Fine book on radiation
 therapy in non-malignant disease, 30
 DHA (an n-3 long-chain fatty acid), e563

Diabetes Mellitus: Rule-change for reporting deaths
 in diabetics, 22, 84, 247, 274
 Therapy of acidosis: Non-random, serial lipoprotein
 changes observed, 315, 335
 DM is a risk-factor for IHD, 247, 350
 DM etiology: Trosko's view, 330
 Impact of anti-biotics, 618
 Dicentric mutation, 46e. Also: 9, 39
 Dietary approaches to prevention and therapy of
 atherosclerosis & IHD, 315, 555-576
 A single regime is not right for everyone, 556-558
 Carbohydrate: 311, 555, 560-561, 572-575
 Animal vs. veg fat: 558-559, 572
 Omega-3 (n-3) fatty acids: 556, 562-564, 566-569
 Being overweight, 556, 569-571
 Difference Cancers (All But Respiratory), e187, e411
 Digital radiography, 34-35
 DiLeonardo (A.) 1993: Gene amplification, 535
 "Disasters-in-waiting," 322-323
 District of Columbia, omitted, 57, 78, 79, 80
 DNA, e537. Diameter of double helix = 2 nm, 38
 Free radicals damage DNA constantly, 38, 530-531
 Unrepaired damage = mutation, 38, 39, 340, 531
 Please see: Repair.
 Dobbin (Mrs. Virginia) 1957, Chief Dietician at Cowell
 Memorial Hospital, UC Berkeley, 556, 558
 Dobson, (R.L.) 1976: LowEnergy radn = extra damage, 47
 "Dogma" falls on role of smooth muscle cells, 323, 324
 "Dogma" falls on severity of stenosis, 322
 "Dogma": Gofman's "heresy" is now "dogma" (1984), 314
 Doll.
 R. Doll, 1976: Smoking-related lung-cancer, 363
 Dollinger (Malin R.) 1965+1966: Heart damage from
 radiation therapy for Hodgkins, 600-601
 Donaldson (S.W.) 1951: Est. xray frequency at mid-
 century, 31, 609-611, 615
 Donner Laboratory, Lipoprotein Studies, 1948-present,
 310-317, 538-561.
 In most of the early work, Frank T. Lindgren, Alex
 V. Nichols, Beverly Strisower, and Oliver DeLalla
 made major contributions beyond the published papers
 which bear their names, 310-314. Additionally,
 Thomas P. Lyon (cardiologist) was indispensable in
 organizing the acquisition of patients for the
 case-control studies.
 Donner Dinner 1990: Gofman 1990-b in Ref. List.
 Dose, ionizing radiation:
 Lowest possible dose & dose-rate, e44, e45, e521,
 e525, e527
 From rads to tracks, conversion, 45, 522, 525
 From bomb-rads to medical-rads, conversion, 48
 Dose is cumulative, 9, 12
 Low, moderate, high dose-ranges, 519
 Entrance-dose versus organ-dose, 519, 611
 Two biggest sources of voluntary irradiation, 536
 Evidence against any safe dose, 44-46, 521-529
 Avg per-capita population dose, 11, 33, 34, 37-38
 Reasons for profound uncertainty, 33-38
 Avg per-patient dose: Likely to be similar in all
 Nine Census Divs, 93-94, 623
 Please see: Dose-units.

Dose-levels from some current xray procedures, 48-49
 "Significant radiological impact" (UNSCEAR), 17
 Examples: CT, Upper GI, Interventional Fluoroscopia, Thallium-201, 48-49. Angioplasty, 36, 600
 Dose-rate per minute from fluoroscopy, 612
 Some procedures often giving over 100 rads, 36, 600
 Model dose-levels vs. true dose-levels, 11, 33
 Measurement of dose seldom done, past or now, 11, 17, 20, 30, 33, 36, 37, 609
 Dose-level varies from place to place, 11, 17, 33
 Dose-level varies with size of patient, 11
 Adult bone-marrow dose, 34
 Doses from cancer radiotherapy, 520, 600, 601, 602
 Please see: Xrays, history, 1960-1999.
 Dose-levels: Natural level vs. acute lethal dose, 520
 Dose rate, minimal, e44, e45, e521-522, 527
 Nuclear workers accumulate mutations from receiving low-doses of radn at minimal dose-rate, 9, 521
 Dose-reduction, achievements & opportunities: 515, 536
 Demonstrated ways, 2, 9, 17, 18, list 23, 33, 35, 36
 Doses cut to one-third in actual practice, 51
 Fluoroscopy, 23, 36
 Mammography, 2, 18
 Spine exams for scoliosis patients, 17-18
 Chest films, 34
 Proper processing of films, 35
 Collimation of beam to organ, 34
 Measurement: A key requirement, 18
 Leaders in professional education: Gray & Mettler, 9
 Hippocratic Oath, 18
 Cases already "in the pipeline," 91
 Dose-response, explained, 53, 55, 96, 111, 212
 Quantitative variation in cause controls quantitative variation in effect, 96, 209, 212, 296
 Example of an ABSENT dose-response, 161-163, 167
 Presumptive evidence of causation, 55, 296, 513
 Please see: Causation.
 Leveling-off (flattening) at high doses, 43, 520
 Add'l entries: Linear. Supra-linear. J-shaped.
 Dose-units of ionizing radiation: 517-519
 Double-strand chromosome breaks 8, 38-9, 526, 527, 528
 The "hallmark" of radn-induced mutations, 528
 Repair is error-prone, 45, 528
 Doubling-dose, e9, e39. DD is low for radn-induced mutations, 5, 7, 9, 39 (in rads), 343, 515
 Doud (A.) 1964: Smooth muscle cells of athero, 301
 DS86 dosimetry, A-Bomb Study, 43
 "Duck" adage: "If it walks like a duck ..." 298
 Duff (G. Lyman) and Gardner MacMillan, 1948+1949:
 Crucial experiments on cholesterol-fed alloxan diabetic rabbits, 539
 G. Lyman Duff Memorial Award, viii, 303, 314, 577
 Dunsmore (Lillian D.) 1986: Heart damage from radn therapy shows "striking difference" from atherosclerosis, 605-606
 Dunsmore (Richard) 1986+1996: Heart damage from high-dose radiation, 605, 606
 Duplex (DNA), e528. The double-helix.

Dysfunctional SMC Mini-Tumors: How they arise and what they do, 340-342
 Numerous genetic pathways to SMC dysfunction, 341
 Expanding plaque may acquire normal SMCs too, 347
 Mutation-induced dysfunction may occur also in non-SMC arterial cells, 339

E

Easton (Alyssa), CDC Office on Smoking & Health, 365
 Educational level vs. smoking habits, 364, 368
 Edwards (A.A.), NRPB rejects threshold, 527
 Effective dose equivalent, e518-519
 Effusion, presence of escaped fluid, 602
 Einstein (Albert) himself would produce false answers from a false database, 216
 Electrons: Endowed by radiation with biologically unnatural kinetic energy, 8
 Elkeles (Arthur) 1961+1966+1968+1969+1977: Reports high alpha-radiation levels in plaques, 329
 Embolus, embolism, e276
 "Emphatic assurances of safety," (examples), 31, 32
 Emphysema and smoking, 362
 Enas (E.A.) 1998: Serum triglyceride & atheroscl, 316
 Endocardium, e599
 Endothelial cells of vessels, e299
 Various functions of arterial endothelium, 307
 Lipid-lowering may improve their function, 345
 Endo. intact at sites of early athero lesions, 307
 Permeability of endothelium to solutes in the bloodstream, 310, 316-318.
 Lipids enter intima without endothelial injury, 318
 Endothelium & damage by high-dose radiation, 607
 Engelberg (Hyman), valued member of Donner group; cardiologist:
 1952a+b: Aberrant lipoprotein levels, diabetes, 543
 1996: Deficient endogenous heparin & atheroscl, 350
 Entrance dose, e611
 "Entropic circumstances" in epidemiology, e99-100
 Environmental factor = any exogenous factor, 327
 EPA (an n-3 long-chain fatty acid), e563
 Epicardium, e599
 Epidemiologic pitfalls. Please see: Pitfalls.
 Epstein (Samuel): AAAS breast cancer symposium, 51
 Epstein (Stephen E.) 1994: CMV & p53 protein, 309
 Equation for a straight line ($y = mx + b$), e63, e92
 Equation of best fit, e63, e94
 Equilibrium: Entry-exit rates of lipoproteins, e317, 318
 Equilibrium: Production & delivery rates, cancer, e90
 Equilibrium would not be reached by 1940, 624
 Potential pitfall in cancer research, 50
 Error-correction (1952) for measurement of Std Sf 0-12 lipoproteins, 541, 545
 Erythema dose, e28 (early dosimeter for xrays)
 Essential hyperlipemia, 335, 588
 Ester, esterified, e562
 Etiology. The study of the causation of any disease, or the sum of current wisdom about the causes.
 European 1987: IHD therapy, prevention, 336
 Evans (H.J.) 1978+1979: Chromosome damage, radn, 39

Evans (John S.) 1986: "Less than 1% of all cases of breast cancer results from diag. radiography," 500
 Critique of the Evans analysis, 500-501
 Evans (Nancy): Big role in birth of Hypothesis-1, 51
 Evens (Ronald) 1995: "Xray mania" in USA 1896, 27-28
 Excess cases of disease beyond expected, 91, 525
 "Executed in plain view," 14
 Exercise (strenuous) & plaque rupture, 324
 Expert Panel 1993 (USA): Endorses regimes to reduce serum LDL cholesterol levels, 319, 336
 Extracellular matrix = connective tissue, 340
 Extra smoking in MidTrio & LowTrio Census Divs, 381

F

Fabricant (C.G.) 1978: Viral etiology of IHD, 307, 308
 Faggiotto (A.) 1984+1984-b: Early athero lesions, 307
 Fajardo (Luis F.) 1968+1973+1977: Heart damage from radiation therapy, 601-605, 606, 607
 Fallout (radioactive) from bombs, 31-32, 521
 Fat (dietary), 556-576
 Oversimplification of advice, 558
 Animal vs. vegetable is inadequate distinction, 562
 Fatty acid, e562-563
 Fatty streaks of intima, e302. In children, 338
 FDA on fluoroscopic & other xray doses:
 1992: Upper Gastrointestinal Exam, 49
 1994: Advisory on fluoroscopic over-doses, 36
 1994: How many rads = erythema dose, 28
 1994: Current fluoroscopic dose/minute, 612
 Fearon (E.R.) 1990: Sequence of cancer mutations, 535
 Felton (C.V.) 1994: Dietary fatty acids & plaque, 569
 Fenestra (channels), e299, 317, 318
 Fernandez-Ortiz (A.) 1994: Lipid-core of plaque is highly thrombogenic, 323
 Fetal irradiation. Frequency, 17, 30, 342.
 Carcinogenic, 32, 524. Atherogenic, 342.
 Fialkow (P.J.) 1974: Enzymes reveal cell ancestry, 326
 Fibrous cap of athero plaque, e302, e303, e323
 Rupture-prone plaques have thinned fibrous cap & large lipid core, 323
 Maintenance & repair of cap's collagen meshwork, 323
 Dysfunctional SMCs can cause vulnerable cap, 342
 "Fiddlers" with a database, 43
 Films (xray), e30, 31, 33
 How much the sales increased, 1963-1980, 34
 Correct processing would cut xray dose, 35
 Photons which never reach film do the damage, 8
 Finkel (Toren) 1995: p53 gene and viruses, 309
 "First obligation of objective investigators," 216
 First question: Do their radn histories differ? (if two groups have different cancer rates), 536
 Fish oils & health, 563-565
 Flavahan, (N.A.) 1992: LDL-chol. & endothelium, 345
 Flies: Muller's fly experiments, 1927, demonstrate that ionizing radn can cause heritable mutations, 31
 Flotation diagrams in ultracentrifugal analysis of lipoproteins, 334. Flotation rates, 312.
 Fluoroscopy, e11, e28. Xray beam stays "on."
 Non-diagnostic uses (surgery, needles), 2, 9
 Is major source of xray dose, 11, 28, 36
 Please see next column.

Fluoroscopy (continues):

Amer.Canc.Soc.: Try to avoid fluoroscopy, 41
 List of high-dose current procedures, 36
 Past uses. Please see: Xrays, history.
 Ways to cut dose, 18, 23, 36
 Doses seldom measured, even now, 30, 36, 349, 500
 Substantial increase in its use, since 1977, 35
 Serial low-dose exposures provide evidence against threshold hypothesis, 523, 527
 Foam cells, e303, e338. Lipids produce "foamy" look.
 Foam cells produce highly thrombogenic tissue-factor, 322-323
 Focal (local) nature of atherosclerotic lesions, 339
 Explanation proposed, 349
 Folkman (Judah): Pioneering effort to control cancer by inhibiting angiogenesis, 536
 Folsom (A.R.) 1999: Vascular disease & infection, 310
 "Foreign Body Wars," lifelong, in arterial beds, 338
 Out-of-place substances elicit inflammatory response, 305, 310, 338
 Fortmann (S.P.), co-author, Gardner 1996, 586
 Foye (L.V.), co-author, Dollinger 1995, 600
 Fractional Causation, e3, e4, e111, e355, e356, e496
 Frac Causation need not change if MortRates fall or rise, 356, 441, 497, 499
 Calculation from dose-response, 14, 111
 Summary, for 1940 & 1990, for All Cancers and for Ischemic Heart Disease, 21, 490
 Frame-shift, can garble genetic code, 534
 Framingham Study 541, 548, 576
 Findings in 1966 from 12-year follow-up, 546, 577, 579-580, 595, 597-598
 Findings in 1986, Sf 0-20, Sf 20-400, 546-547
 Findings on Sf 20-400, on triglyceride, 565-566
 Francis (G.S.) 1989: How ACE inhibitors may work, 351
 Fredrickson (Donald S.) 1993. Former head of NIH, 314
 History of lipoprotein studies, 311
 LDL vs. total chol. to predict coronary risk, 314
 Freeman (Norman K.), valued member of Donner group, 313, 542. Expert in infrared spectroscopy.
 1952+1953: Fatty acids in triglycerides, 562
 Free radical, e530. Demonstration: Impossible for DNA-damage by radn to be equivalent to DNA damage from routine metabolic free radicals, 530-532
 Frick (M.H.) 1987: Helsinki Heart Study, 336, 565
 Frigerio (N.A.) 1976: Source of "smoking gun," 50
 Frost (Edwin): 1896, first medical radiograph USA, 27
 Fry (D.L.) 1987: How lipoproteins enter intima, 318
 "Full circle" (lipids from start to finish?), 324
 Fungal origin of some carcinogens, 210
 Furberg. (C.D.) 1994: IHD therapy, prevention, 336
 Fuster (Valentin): 300, 304, 317, 321, 322, 325, 337, 338, 348, 349.
 1992: Culprit plaques are lipid-rich, 304
 1994 (Conner Memorial Lecture):
 The history of insights on plaque rupture, 321
 Intimal ingress, egress of lipoproteins, 318
 Plaque rupture, 349. Silent occlusion, 349
 Pharmaceutical IHD therapies, 351-352
 Thrombogenic lipid core of plaque, 323

G

- Gallini (R.) 1985: How to cut xray dose, 23
- Gamma radn, e517. Less mutagenic than xrays, 9, 46-48
- Gardner (Christopher D.) 1996: Data on "small low-density lipoprotein particles," 586, 587-588, 592
- Garlick (D.G.) 1962: How to cross capillary wall, 317
- Gassman, (A.) 1899+1904: Radiation damage to small vessels, 607
- Geer (J.C.) 1961: Smooth muscle cells in plaque, 301
- 1968: Arterial thickening, 338
- Gene, e537
- Gene amplification, e534
- Genentech (comment by Herb Boyer), 55
- Genetic code, e537
- Genetic instability. Please see: Genomic instability.
- Genome, e537
- Genomic imprinting, 325. Also: Lyon 1968 + Hall 1990.
- Genomic instability, e533, 533-536
- Characteristic of aggressive cancers, 7, 8, 39-40
- Explains resistance of cancer to therapy, 536
- Inducible by radn, incl. xrays, 5, 7, 515, 535, 536
- Why cancer called "100 different diseases," 535
- "Giants" (even smallest lipoproteins), 312, 317, 333
- Gilbert (Ethel) 1985: Her risk model, prepared for the Nuclear Regulatory Commission, chosen by Evans
- 1986 to evaluate xray-induced breast-cancer, 501
- Gimlette (T.M.) 1959: Heart damage from radiation, 601
- Giovino (Gary A.) 1994: Per capita cigarette use, 363
- Giroud (D.) 1992: Culprit plaques less stenotic, 322
- Glagov (S.): Pathogenesis of plaques:
- 1972: Sites of hemodynamic stress, 307, 349
- 1987: Lesion first grows away from lumen, 303
- Glazier (Frank) 1954: Serum lipoprotein distributions:
- By age, gender, 351, 576 (graphs)
- Fasting vs. non-fasting, 541-542
- Glycogen storage disease: HDL low, Sf 0-400 high, 577
- High HDL-1, 588
- Gofman (John W.), iv, viii, 17, 19-20
- Entries below are arranged chronologically.
- Uranium & plutonium work for A-bomb, viii, 17
- 1949: Initial paper on serum lipoproteins, 311
- Gofman (J.W.), 1950s: 310-316, 538-554, 556-561
- 1950a+b, 1951a+b: Entry to "new world of diverse lipoproteins," 311-314, 539-540
- First human case-control results in 1950 for Sf 10-20 lipoproteins, 540, 544
- 1952-a: Sf 20-100 lipoproteins also atherogens, 540.
- Sf 0-12 measurements need adjustment, 541. Which lipoprot groups are INDEPENDENTLY atherogenic? 543
- 1952-b: Overweight & abnormal lipoprot levels, 543
- 1952-c: Lipoproteins in a metabolic chain, 540.
- Some of the case-control evidence that Sf 12-20 & Sf 20-100 are each independent atherogens, 552
- 1952-d: Involution of xanthomas after lipid-reduction, 543. Massive elevation of HDL-1, 588
- 1953: Sf 0-12 also recognized as atherogenic, 541.
- Mid-1953 database: 239 IHD cases, 740 controls 540
- 1954-a: HDL2+3 inversely corr w Sf 0-400 in healthy people, 577. HDL levels in nonIHD disorders, 577.
- Interclass correlations among lipoproteins, 544
- Gofman (J.W.) continues:
- 1954-d: Power of lipoprot measurements, to segregate cases vs controls, is lower in older groups, 546
- 1954-e: NonIHD disorders which show aberrant lipoprotein levels, 543, 551
- 1956: Cooperative (prospective) Study, 544-546
- First evidence, high lipoproteins precede IHD, 545
- 1958: High-carbo diet raises TG, 315. Evidence that, to manage blood lipoproteins, no single dietary regime is right for everyone, 556-561
- Involution of xanthomas w lipid-reduction 543, 575
- 1959: Involution of xanthomas after lipid-lowering, 543, 561
- Gofman (J.W.), 1960s (from Donner to Livermore, 1963).
- 1963: Entry, egress, retention of lipoproteins in the intima (equilibrium model), 316-317. Relative thickness of layers of coronary arteries, 300
- 1966 (Lyman Duff Lecture): Reported results from 2 prospective studies (Framingham and Livermore) on lipoproteins & IHD death, 546-548, 577, 591, 594-597
- One clinically disappointing aspect, 594
- First prospective confirmation that HDL2+3 is inversely correlated w atherogenesis, 314, 577
- 1969: Predicts that small reduction in degree of coronary atherosclerosis should produce a big reduction in IHD, 321
- 1969-b: Start of Gofman-AEC troubles, 533
- Predicts nearly all cancers are radn-inducible, 40
- Gofman (J.W.), 1970s:
- 1971: Track-analysis vs dose-rate claims, 521
- "Spontaneous" cancer-rate includes Xray-induced cases, 50
- 1976: Est lung-cancers from plutonium pollution, 517
- 1978: Basis for doubt that HDL2+3 is an independent anti-atherogen, 577
- Explanation of apparent decline of importance of Sf 0-400 lipoprot levels at older ages, 594-598
- Gofman (J.W.), 1980s:
- 1981 book, iv. Data on radn-induced breast-canc, 51
- Track-analysis vs threshold hypothesis, 521
- Neutron-error in A-Bomb Study, 43
- Full-lifespan risk from radiationn-exposure, 50
- "Smoking gun" on medical xrays, ignored, 50
- Probably no minimum latency period, 91
- Radn-induced non-malignant tumors, 297
- 1985 book, iv. Reviews, 51
- Progress in beam-collimation, 34
- Ratio of surface dose to internal dose, 49, 519
- Dose-cut could prevent 50,000 canc/yr, USA, 51
- 1986: Track-analysis vs threshold claims, 521
- 1988: Peril for A-Bomb Study's credibility, 43
- Gofman (J.W.), 1990s:
- 1990 book, iv.
- Primary ionization tracks (behavior), 38
- Peril for A-Bomb Study credibility, 43-44, 54
- Constant-Cohort, Dual-Dosimetry demonstrated, 44
- Evidence against threshold-dose for mutation 44-45
- Xrays more mutagenic than gamma radiation, 46
- Number cell-nucleus traversals to deliver rad, 47
- Ballpark est: Radn causes 25% of cancer (USA), 51
- Iodine-131-induced Thyroid Cancer, 91
- Adaptive cellular responses to radiation, 617

Gofman (J.W.) continues:

- 1990-b: Hows & whys of early lipoprotein work at Donner Lab, 311
- 1992: How to maintain bias-free radn research, 43
- 1994 book, iv. Probably no minimum latency period 91
- Exposure to alpha-particle pollution, 517
- Inherited predisposition to cancer, 496
- 1995, 1995/1996, 1996 book (1st + 2nd Editions):
- Why it was written, 51. 2nd Edition additions, 52
- No overlap between data & method of that book and this monograph, 15, 500. Nonetheless both works arrive at nearly the same Fractional Causation of current Breast-Cancer rate by radiation, 501
- History of pre-1960 xray use, 30, 31, 33
- Age & radiosensitivity, 37
- "Law of Equality" and flat cancer rates, 90
- 1996-b: How and why the Donner group did what it did, 311
- 1998: Inherited disorders & natural radn, 520
- Gold (Harold) 1961+1962: Synergism between radn and dietary cholesterol in experimental animals, 604
- Goldman (L.) 1983: Value of autopsies, 81
- "Gold standard" in establishing causation, 213, 513
- The blind prospective study, 213
- Gordon (David J.) 1989: Doubtful that HDL is anti-atherogenic, 577-578
- Gornik (H.L.), co-author of Bailar 1997, 82
- Gould (A.L.) 1995: IHD therapy, prevention, 336
- Graham (J.) 1967: Talc, asbestos, ovarian cancer, 163
- Gram of cells contains approx 675 million cells, 518
- Grattan (M.T.) 1989: CMV infection & atheroscl, 308
- Gray (dose-unit), e517. 100 rads.
- Gray (Joel): A leader in xray dose-reduction, 9
- 1983: How to cut dose for scoliosis patients, 17-18
- Greenfield (Maurice M.) 1986: Book review, 51
- "Grenades": Violent energy-deposits by radn 8, 38, 517
- Grove (Robert D.) 1968: 1940-1960 MortRates, 78, 83, 84, 87
- Age-adjusted MortRates, e83
- Changes in rules for choosing underlying cause, 84
- History of MortRate data, USA, 77-78
- No IHD data before 1950, 279
- List of 32 causes of death, 84-86, 224
- Provides some population data, too, 58, 75, 616
- Gruppo 1986: Thrombolytic treatment of MI cases, 322
- Gupta (S.) 1997: Infectious etiology for IHD, 309
- Gurd (F.R.N.) 1949: Alpha & beta lipoproteins, 311
- Guyton (J.R.) 1985: Lipid transport to core, 318
- Gyorkey (F.) 1984: Herpesvirus & atheroscl, 307, 308

H

- Hackett (D.) 1988: Culprit plaques less stenotic, 322
- Haft (Jacob I.) 1997: Plaque rupture and heart attacks after snow-shoveling, 324
- Hajjar (D.P.) 1988: Infectious etiology & IHD, 307
- Hammerstein (G.R.) 1979: How to cut xray dose, 23
- Hammond (E. Cuyler) 1961: Smoking habits USA, 364
- Hammoudeh (A.J.) 1996: Warning on snow-shoveling, 324
- Hardin (N.J.) 1973: Injury to endothelium, 306
- Harker (L.A.) 1974+1976: Injury to endothelium, 306

- Harris (William S.) 1989: Fish Oils and Plasma Lipid and Lipoprotein Metabolism in Humans: A Critical Review, 556, 562, 563-565, 568
- "Good reasons" to worry about high serum VLDL, 565
- Harvey (Elizabeth B.) 1985: Prenatal xrays, 524
- Haskell (W.L.) 1994: IHD therapy & prevention, 336
- "Hat": "I'll eat my hat if ..." 509
- Haust (M.D.) 1960+1971: Plaque's nature, 301, 302, 318
- Havel (Richard J.) 1995: IHD therapy & prevention, 336
- Hawaii, omitted, 57, 78, 79, 80
- Hayes (Thomas L.), valued member, Donner group, 542
- Studied lipoproteins via the electron microscope.
- HDL (high-density lipoproteins HDL2+3), e312-313, e333
- Protective "good cholesterol," 313, 314, 577
- Basis for doubt, 314, 577-585
- HDL correlates inversely w. LDL+IDL+VLDL in clinically healthy people on the average, 579, 582
- HDL values: Low in various clinical disorders, 577
- HDL-1 is truly a LOW-density lipoprotein, 313, 335, 587, 589
- "Small, dense LDL particles," 313, 586-593
- Not elevated in 38 Livermore de novo IHD cases 577
- Massively elevated in "essential hyperlipemia," 335, 588
- Heart attack = Myocardial Infarction (MI), 276
- Number/year in USA, & fatal percentage, 276
- Heart damage from high-dose radn, 1, 9, 16, 275
- Nature of the injuries, 599-608
- Heart diseases which are not IHD, e276-278
- Sorted by their ICD/9 numbers, 277
- Heath (Clark W., Jr.) 1995: Embraces the Evans 1986 estimate that xrays have minor cancer role, 500
- Hebert (P.R.) 1997: Statin trials & cancer, 320
- Hegsted (D.M.) 1998: Carbohydrate effect on TG, 560
- Hei (Tom K.) 1997: Mutation by single alphas, 529
- HelicoBacter pylori. And IHD, 309. And stom canc, 435
- Helin (P.) 1971: Injury to endothelium, 306
- Henderson (W.J.) 1971: Talc, asbestos, ovarian ca, 163
- Heparin (endogenous) & IHD risk, 350
- Hepatitis (acute): HDL low, Sf 0-400 high, 577
- Hepatitis virus and liver cancer, 496
- "Heresy" becomes "dogma," 314
- Herpes Simplex Virus (HSV) & IHD, 307, 308
- Hetzel (Alice M.), co-author of Grove 1968, 78
- Hickey (P.) 1923: Internists & fluoroscopy, 29, 609-10
- High-5 and Low-4 Census Divisions, e60, e77
- High-density lipoproteins: Please see HDL, above.
- High dose-level, e519
- High-dose heart damage. Please see: Heart damage.
- High-dose thymus irradiation, tonsillectomy, 28
- Hill (C.R.) 1965: Cig. smoke and polonium-210, 362
- Hill (Rolla B.) 1992: Autopsy data, 81, 82, 510
- Hippocratic oath & reducing uselessly high doses, 20
- Hiroshima-Nagasaki: Please see A-Bomb Survivor Study.
- "Hive of activity" (plaque), 339, 347
- Ho.
- Gloria Ho, 1998: HPV and cervical cancer, 164
- Hodgkins Disease, radiotherapy, & heart damage, 600, 601, 602, 603, 604, 605
- Hodis (Howard N.), completed David H. Blankenhorn's last paper, 303

Hoel (Donald), co-author of Shimizu 1992, 501-502
 Hokanson (J.E.) 1996: Triglyceride and IHD, 316
 Holm (Lars-Erik) 1988: Latency for thyroid cancer, 91
 Holmberg (K.) 1993: Radn and genomic instability, 535
 Holme (I.) 1990: IHD therapy, prevention, 336
 Holmes (M.D.) 1999: Dietary fat & breast cancer, 569
 Holtzman (R.B.) 1966: Cig. smoke & polonium-210, 362
 Homocysteine, e331. And IHD, 306, 331-332, 350
 Hormesis, e617. Speculation that low doses might improve health, 525. Adaptive responses, 527, 617
 Hormetic illusion fr "perfectly good data," 617-620
 Howe (Geoffrey R.) 1984: Cancer from serial exposures to very low-dose fluoroscopy, 523
 HPV = Human Papilloma Virus, e164
 Hrubec (Zdenek) 1989: Cancer from serial exposures to very low-dose fluoroscopy, 523
 Hsieh (W.A.) 1999: Gamma-induced translocations, 39
 Hu.
 F.B. Hu, 1998: Carbohydrate effect & IHD risk, 560
 Huda (Walter) 1984: How to cut xray dose, 23
 Huff (H.) 1972: Heart damage by radn therapy, 603-604
 Hulley (S.B.) 1992: IHD therapy, prevention, 336
 Hurst (D.W.) 1959: Heart damage by radn therapy, 601
 Husik (D.N.) 1926: Skin damage as xray dosimeter, 28
 Hyalinization, e606
 Hypercholesterolemia: Synergism with radn in rabbits, rats, pigeons, 604-605
 Hyperinsulinemia & IHD risk, 350-351
 Hypertension: Decline in death-rate, 287, 350, 499
 Hypertriglyceridemia, e560, e563
 Hypothesis-1: What it is NOT, 2, 100, 209-210, 214, 215. Why it may be hard to devise a more reliable test of Hypothesis-1 than the tests in this book, 19, 501
 Hypothesis-2: This monograph presents the first powerful epidemiologic evidence that ionizing radiation is a cause of IHD, 2, 502
 Validity of the first part of Hypoth-2 does not depend on validating its second part, 19, 298

I

IARC = Internatl Agency for Research on Cancer, e41
 No monograph yet on ionizing radiation, 41
 IARC 1995: Human papilloma virus & cervical canc, 165
 ICD = Internatl Classification of Diseases, e80, e84, and WHO 1958 in our Ref. List.
 ICRU 1986: Mutagenic potency of xrays, 46, 47
 Ideal data & circumstances for studies like this, 62, 90, 96, 100
 IDL = Intermediate-Density Lipoproteins, e312
 IHD = Ischemic Heart Disease, e275, e595
 Other names, 1, 7, 233. Two phases, 595
 Acute IHD events, e276, e318, e347
 "Diseases of the heart" OTHER than IHD, 276-278
 IHD dose-response with PhysPop, 13, 25, 279-294, 477-488
 Etiology of IHD, Chapters 44, 45, 46
 Heart damage fr high-dose radn is not IHD, 599-608
 Number IHD deaths (1993, USA) = 489,970 (21.6%), 276
 Age-adju MortRates differ, males vs females, 483
 Age-adju MRs falling since 1963, 287, 288, 477

Illingworth (D. Roger): Dietary n-3 fatty acids, 563
 Inagaki (M.) 1988: Dietary n-3 fatty acids, 564
 Incidence (cancer), recent trends, 506
 Infections as atherogens, 306, 307-310
 As carcinogens, 41, 164-165, 435, 496
 Inflammatory response, e305. Systemic, 306
 Operation in its "full majesty," 342
 Inflammatory disorders received radiotherapy, 30
 Inherited afflictions, partly from natural radn, 520
 Inherited mutations, 3, 4, 20, 31, 92, 377, 496, 520
 Inherited predisposition to atherosclerosis, 351
 Inherited predisposition to canc, 3, 51, 164-65, 495-6
 Initiation-promotion (cancer), 3, 114, 330, 376, 495
 Radiation may act at any stage, 526
 "Innocent bystanders," Chlamydia infection maybe, 310
 Insurance (medical), mid-century, 31, 618
 Enactment of entitlements, 54, 57, 60
 Cost-cutting pressure on quality-assurance, 35
 Integrated exposure over time to plasma lipoproteins, 595, 596, 598
 Internal elastic membrane of coronary arteries, e299
 International Classification of Diseases, 80
 International Commission on Radiol. Protection, 519
 Interventional radiology, e9, e28
 "Substantial increase" 1977-1997 in fluoroscopy, 35
 Intima, intimal layer of artery, e299. Thickness 300
 Intimal thickening begins in childhood, 338
 In-utero irradiation, frequency, 17, 30, 342
 Cancer-consequences, 32, 524. IHD conseq, 342
 Inverse (negative) correlation, e99, e105
 In vitro = in laboratory glass, 5
 In vivo = in a living organism, 5
 Iodine-131-induced Thyroid Cancer, 91
 Ionizing radiation, e38, e517.
 Ionization track, e38, e521, e525
 Unique mutagenic powers, 8-9, 38-40, 297, 343, 526, 528, 532, 536
 All types of mutations radiation-inducible, 9, 40, 526, 528, 535, 536
 Access to every gene in every cell, 8, 40, 341
 An established cause of cancer, 2, 7, 9, 40, 41, 297
 Powerful new confirmation, 216
 An established cause of benign tumors, 297
 Heritable radn-induced mutations, first demo, 32
 Delivery by radioactive fallout, nuclear pollution, and medical procedures, 32
 "Irrefutable facts," not interpretations: 215, 295, 337, 343, 510, 513, 514, 515
 Ischemia, e275
 Isherwood (I.) 1978: How to cut xray dosage, 23
 Itching (incessant), treated with radiotherapy, 30
 Iverius (P-H.) 1973: Retention of LDL in intima, 318

J

JAMA = Journal of the American Medical Assn, 310
 Jankowski, (J.) 1984: How to reduce xray dose, 23
 Johnson (D.W.) 1986: How to reduce xray dose, 23, 34
 Johnson (F.L.), co-author, of Rudel 1986, 564
 Joint 1990: IHD therapy, prevention, 336
 Jonasson (L.) 1986: Composition of plaque, 303
 Jones (A.) 1960: Heart damage by radn therapy, 601

- Jones (F.) 1996: Lyon Diet Heart Study, success, 567
 Jones (Hardin B.) 1951: An early and key member of the Donner lipoprotein group, 312, 313, 539, 540, 542, 544, 553, 554
 Sf 20-100 lipoproteins also atherogenic, 540
 Independent atherogenicity, 543-544, 553-554
 Lipoproteins as molecules in metabolic chain, 542
 J-shaped dose-response curve, e617, e620
 Juchau (M.R.) 1974: Cig. smoke reaches placenta, 327
 Jukema (J.W.) 1995: IHD therapy, prevention, 336

K

- Kadhim (Munira A.) 1992+1994+1995: Radn-induced genomic instability, 535
 Kallioniemi (Anne) 1992: Techniques for detecting genomic instability, 534
 Kane (John P.) 1990: IHD therapy, prevention, 336
 Kardinal (A.F.M.) 1993: Plasma n-3 fatty acids, 568
 Katan (Martijn B.) 1995: Dietary fish-oil, effects on serum lipoproteins, 563-564
 Also, please see Connor 1997 in Reference List.
 Kato (Hiroo): A-Bomb Study and IHD, 501-502
 Kazakov (V.) 1992: Thyroid cancer latency < 5 yrs, 91
 Kellner (Albrecht) 1987: Gene repair-system, 523
 Kellner (A.) 1954: How to cross capillary walls, 317
 Kelly (Kevin M.) 1975: Frequency, prenatal xrays, 30
 Kemp (C.J.) 1993: Sequence of genetic mutations, 535
 Keys (Ancel) 1984: Diet and IHD rates, 568
 Kidney stones & xrays, 35
 Kim (D.N.), co-author of Thomas 1983, 328
 Klausner (Richard D.), NCI Director: On tobacco, 363
 Knapp (H.R.) 1986: Fatty acids & thrombogenesis, 569
 Knopp (Robert H.) 1997: Effect of high carbohydrate diet on serum triglycerides, 555, 560
 Kodama (Yoshiaki) 1993: Radiation-induced chromosomal mutations persist at least 40 years, 50
 Kol (Amir) 1997: Work related to Speir 1994, 309
 Kolb (Felix O.) 1955: Diabetic acidosis demonstrates intersection of sugar metab & lipid metab, 315, 335
 Excess small dense LDL (HDL-1), 335, 543, 588
 Kramsch (D.M.) 1971: Features of plaque, 303, 305
 Krauss (Ronald M.):
 1987: LDL, IDL, VLDL ranges in Std Sf units, 312
 1994: Small, dense LDL particles, 586
 1996: Co-author of Gardner 1996 + Stampfer 1996, 586
 Krieger (Lisa M.) 1996: Xray work by non-radiol, 35
 Kromhout (D.) 1985: Dietary n-3 fatty acids & IHD, 565
 Kronenberg (A.) 1994: Genomic instability fr radn, 535
 Ku.
 D.N. Ku, 1985: Plaque sites and hemodynamics, 349
 Kucerova (M.) 1972: Low doubling-dose for chromosomal mutation by ionizing radiation, 39
 Kuhn (H.F.) 1985: How to cut xray dose, 23
 Kuntz (A.) 1949: How do lipids get into plaque? 542
 Kushner (I.) 1999: Inflammation, 306
 Kwiterovich (P.O.), co-author, of Coresh 1996, 586

L

- Lamarche (Benoit) 1997: Serum triglyceride & IHD, 316
 "Small, dense LDL particles," 586

- Lamberts (H.B.) 1964: Heart damage fr radiation, 604
 Landis (S.H.) 1998: Leukemia rate, USA, 43
 Landrigan (P.J.) 1989+1996: Workplace carcinogens, 495
 Latency periods = post-irradiation intervals before delivery of clinical cases of disease, e49, 92
 Spread out over 40-50+ years in irradiated mixed-age group, 12, 49, 52, 89, 100, 210
 ~40 different latencies in mixed-age population, 89
 Variable even among persons exposed at same age, 49
 Probably no MINIMUM latency period, 91-92. Why, 92
 Exposure before & after 1921 contributes to cancer-rates in 1940, 108, 212
 Exposure in 1920 contributes to 1965 canc-rate, 52
 Exposure in 1950 contributes to cancer today 32, 356
 Cases "in the pipeline" from earlier exposure, 91
 Laurent (T.C.) 1963: LDL retention in plaque, 318
 Lavine (D.M.), co-author of Dollinger 1965, 600
 Law of Equality (cancer production & delivery), e90, e101 (depicted)
 Law of Minimum Hypotheses, e215, e512, 644
 Laws (Priscilla) 1980: How to cut xray dose, 23
 LDL = Low-Density Lipoproteins, e312, e333
 Lead-210, a radionuclide, e329. In cigarette smoke.
 Leading causes of death, USA (absolute numbers), 278
 Leaf (Alex.) 1999: Mediterranean Diet & IHD, 566
 Leary (T.) 1949: How do lipids get into plaque? 542
 Leddy (Eugene T.) 1937: No investigation of a patient is considered complete without xray exams which generally include fluoroscopy, 29, 610
 "Legitimate" questions: BEIR says "legitimate" questions exist because some low-dose studies produce risk-ests "substantially" higher than its own, 11
 Leibovic (S.J.) 1983: How to cut xray dose, 23
 Lesion = an injury or loss of function.
 LET.
 LET = Linear Energy Transfer, e47, e518
 Relationship with mutagenic potency, 47-48, 518
 Relationship with initial energy, 518
 Low-LET radns include xray, gamma, beta, 521
 High-LET radn includes alpha particles, 528, 529
 Lethal acute dose of ionizing radiation, e520, e531
 "Lethal diagnostic weapon" (Braestrup 1942), 29
 Leukemia: Percentage of all cancers, USA, 43
 Xray-induced, 32. Bomb-induced, 32, 43.
 Libby (Peter) 1995: Molecular Bases of the Acute Coronary Syndromes: 303, 317, 318, 320, 321, 322, 323, 324, 337, 338, 340, 342, 345.
 His paper inspires a "massive shift" in our thinking on the role of SMCs in deadly IHD events, 323
 T-cells can inhibit the collagen-synthesis (by SMCs) needed to maintain & repair fibrous cap, 323
 Libby's view: Integrity of fibrous cap determines stability of plaque, 323
 Libby asks: What makes CERTAIN plaques rupture-prone? 337, 342
 Libby urges caution about therapies designed to inhibit SMC proliferation, 324
 Lipid-imbibing foam cells produce highly thrombotic tissue-factor, 322-323
 SMCs express both matrix-protecting & matrix-degrading enzymes, 340
 Libby (Peter) 1997: Infection & vascular disease, 310

Library (medical) at UCSF, 52
 Lichtenstein (D.A.) 1996: Cumulative skin-dose from fluoroscopy today can reach 1000-3500 rads, 600
 Linder (D.) 1965: Detecting monoclonal lesions, 328
 Linder (Forrest E.) 1947: 58, 83. Age-specific cancer death-rates, USA, 1900 through 1940, 87, 504
 Lindgren (Frank T.), Pioneer-work at Donner Lab in ultracentrifugal isolation and characterization of human blood lipids, viii, 313, 542. Co-author of the initial paper (Gofman 1949).
 1950+1951: Entry into "the new world of diverse lipoproteins," 311, 312, 313, 334
 1955+1956+1957: 333, 542, 550
 1959: Includes excellent overview of lipoprotein composition, 333, 542, 549, 550
 1960: Please see Reference List.
 Linear dose-response, e42, e92-93
 And PhysPop studies, 93-94
 And A-Bomb Study, 42-43
 Linear energy transfer (LET). Please see: LET.
 Linear-quadratic dose-response, e42
 Linear regression analysis, e12, e13, e94, 108-110
 Line of best fit, e63, e94
 Linoleic acid (n-6), e563
 Linolenic acid (n-3), e563
 Linser (P.) 1904: Radiation damage to vessels, 607
 Lipid 1995:
 Long-term Pravastatin study, 320
 Lipid Hypothesis, e310, e595.
 Please see: Plasma lipoproteins: Lipid Hypothesis.
 Lipid-lowering. Please see: Stabilization of plaque.
 And: Dietary approaches.
 LipidRC 1984: IHD prevention trial, 336
 Lipoproteins of the bloodstream: e310, e556
 Please see: Plasma lipoproteins.
 Lithotripsy for kidney stones, 35
 Little (J.B.) 1965: Polonium-210 in cig. smoke, 362
 1997: Risks from alpha-radiation, 529
 Little (M.P.): NRPB rejects threshold, 527
 Little (W.C.) 1988: Degree of stenosis, 322, 348
 Liuzzo (G.) 1994: C-reactive protein and IHD, 306
 Liver cancer and the hepatitis virus, 496
 Liver cells in illustration of co-action, 497
 Liver (cirrhosis), diagnostic problem, 81
 Livermore Lipoprotein Study, 314, e547. Provides data:
 HDL & atherogenic lipoproteins are inversely correlated, 578-585
 "Small dense LDL particle" analysis, 588-593
 Frequent weight-change & "snapshot" epid'y, 595-598
 Heavier weight, higher Sf 0-400 on average, 570-571
 Lloyd (D.C.) 1986+1992: Radiation-induced chromosomal mutations, 39, 46
 LMDS = Locally Multiply Damaged Sites, e528
 "Lockstep," e61
 Longo (D.L.) 1979: Talc, asbestos, ovarian canc, 163
 LoPonte (M.A.), co-author of Dunsmore 1986, 605
 Lorie (H.M.) 1992: Fibrous cap of culprit plaques, 323
 Los Angeles Civil Service, lipoprotein database, 541
 Low-density lipoproteins, initial definition, 312, 333
 Current definition, 312
 "Small, dense LDL particles," e587
 Low dose-level, e519

Lucas (Joe N.): Pioneer in detecting chromo mutations.
 1992: Low doubling-dose for mutations by radn, 39
 1992: Persistence of A-bomb-induced mutations, 50
 1995: Xrays more mutagenic than gamma rays, 47
 1997: New techniques to detect mutations, 39
 1999: Accumulated translocations rise with age, 39
 Lumen = the clear, circular space within a tube, 275
 Lyon Diet Heart Study (Mediterranean Diet), 566-569
 Possible reasons for success with IHD patients, 569
 Lyon (M.F.) 1968: Females inactivate one X-chromo, 325
 Lyon (Thomas P.). Please see: Donner Lab.

M

Ma.

Jing Ma, co-author of Stampfer 1996, 586
 MAAS 1994: IHD therapy and prevention, 336
 MacIsaac (A.I.) 1993: Stabilization of plaque, 325
 MacKee (George M.) on history of medical radiation:
 1922: High-dose xrays used on 80 skin disorders, 30
 1938: "Radiomaniacs" in xray practice 1896-1906, 28
 MacKenzie (Ian) 1965: Classic paper (Nova Scotia data) uncovers relation of serial low-dose fluoroscopy with breast cancer, 523
 MacMahon (B.) 1962: Rate of pre-natal xrays, 30, 524
 Macrophage, e303
 Magnetic resonance imaging & vulnerable plaques, 323
 Mahan (Bruce H.) 1975: Utility of ideal models, 62
 Majesky (M.W.) 1985: Mutagens & some atheromata, 327
 "Majesty" of the inflammatory response, 342
 Malinow (M.R.) 1994: Homocysteine & artery health, 331
 Mammography: Model of success in dose-reduction, 2, 18
 Use rises while dose falls, 2
 Risk from low-energy xrays, 47 (Brenner 1989).
 "Man is not a rabbit!" 539
 Marder (B.A.) 1993: Radn & genomic instability, 535
 Margolis (S.) 1969: LDL carries benzo[a]pyrene, 327
 Marine oils (fish oils) & IHD, 562, 563
 Martell (Edward A.), fine chemist, fearless thinker:
 1975: Hypothesis that cigarettes cause IHD by delivering alpha radn to coronary arteries, 329, 350
 1974 + 1982a + 1982b + 1982c + 1983a + 1983-b:
 Hypothesis that cigarettes cause lung cancer by delivering alpha radn to bronchi, 362
 Marx (J.) 1994: Benditt monoclonal hypothesis, 331
 Marzetta (C.A.), co-author of Rudel 1986, 564
 Maseri (Attilio) 1997:
 IHD appears ever more complex, 300
 Plaque rupture is not the whole story, 324
 New hypothesis needed for IHD etiology, 337
 Mass 1890:
 Massachusetts 1890 MortRates, 78
 Massachusetts General Hospital, 28
 "Massive HDL-1 Hyperlipoproteinemia Syndrome," e587
 Masuda (J.) 1990+1990-b: Plaque begins at sites of intact endothelium, 307
 Matching, e98. Essential in dose-response studies, 56, 99, 512, 617. But always imperfect, 98, 99
 Matching for age, 11
 Matching for co-actors, 98, 618
 Matching for smoking, 367, 378-379, 621-624
 Effect of not matching. Please see: Non-matching.

- Maurer (Jeff) at National Center for Health Statistics was very helpful in providing MortRate data, 79
 "Mayhem" for irradiated molecules, 8, 38, 520
 Mayo Clinic, 9 (Gray). 29, 610 (Leddy).
 McCully (K.S.) 1969: Concept that high blood-levels of homocysteine are a cause of cardiovasc. disease, 331
 McDonald (K.) 1989: Viral etiology of IHD, 307, 308
 McGill (Henry C.) 1984: Lyman Duff Lecture, 314, 338
 McGinley (James P.) 1952: Lipoproteins in steady-state concentration, 542. In biliary cirrhosis, 543.
 In xanthomas, 543
 McLennan (P.L.) 1993: Fatty acids & arrhythmias, 569
 McMillan (Gardner) 1949: Remarkable cholesterol-fed rabbits, 539
 McNeil (B.J.) 1985: Breast-irradiation in 1977, 500
 McReynolds (R.A.) 1976: Heart damage from radn, 604
 Measurement of dose: Key to dose-reduction, 18
 Not required, seldom done, easy to do, 33
 True organ-doses vs. model-doses, 11, 33
 Media (layer of artery), e299
 Medical radiation, e2, e5, e7, e9. Add'l entries:
 Benefits. Dental xrays. Nuclear medicine. Xrays.
 Medicare, enacted in 1965, 57, 60, 498
 Mediterranean Diet --- Why do the Lyon Study
 Investigators think it "works?" 568-569
 Meier (C.R.) 1999: Infection & infarction, 310
 Melnick (J.L.) 1990: Viral infection & IHD, 307-308
 Mendall (M.A.) 1994: Bacterial infection & IHD, 309
 Mendonca (M.S.) 1993: Radn & genomic instability, 535
 Mensink (R.P.) 1992: Carbohydrate & plasma TG, 560
 Mettler (Fred A., Jr.): How to cut xray dose, 9
 1987: Number of xrays during 1964, USA, 611
 MI.
 MI = Myocardial Infarction (heart attack).
 Migration between Census Divisions, 56, 100, 511-512
 Miller (A.B.) 1989: Serial low-dose fluoroscopy, 523
 Milli-rad, e517. 0.001 rad. 10⁻³ rad.
 Minick (C.R.) 1973: Injury to endothelium, 306
 Minimum latency period, post-irradn: Maybe none, 91-92
 Mini-tumors in the coronary arteries, e297, 298, 327
 Minkler (Jason L.) 1970+1971: Livermore Laboratory.
 Chromosomal pathways of cancer, 533
 Demonstrates gamma-induced genomic instability, 535
 Misdiagnosis of cancer: Frequency & impact, 81-82, 510
 Stomach canc maybe reported as ulcer-death, 22, 274
 Mitochondrial DNA, e537
 Mitogenic = stimulating cell-division (mitosis), 306
 MMWR = CDC's Mort & Morbidity Weekly Report, e363
 1987: Percent smokers in 1986; peak years, 365
 1988: Autopsy rates, USA, 81
 1994: Cigarettes/year, USA, 363, 364, 371, 372
 1996: Smoking prevalence by states, 1995, 365, 366
 Modan (B.) 1977+1989: Cancer from few tracks/cell, 524
 Moderate dose-level, e519
 Modern Medicine 1949: Who owned xray machines, 615
 Moeller (Dade W.) 1953: Mid-century estimates.
 Entrance dose per fluoroscopy = 65 R, 30, 611-612
 Entrance dose per dental xray = 5 R, 31
 Number of xray exams per year & avg. doses, 609-612
 Monoclonal, clone, e325.
 Monoclonal hypothesis of atherosclerosis introduced
 in 1973 by Earl Benditt et al, 1, 6, 16, 325-327
 Other supporting evidence & supporters, 327-331
 Montanara (A.) 1986: How to cut xray dose, 23
 Moore (Felix E.), admirable insistence on rules of
 "blinding" in lipoprotein studies, 546
 Moore (S.) 1973: Endothelial injury & atheroscl, 306
 Moorjani (S.), co-author of Lamarche 1997, 586
 Moreno (P.R.) 1994: Stabilization of plaque, 325
 Morgan (Karl Z.), pioneer in health physics.
 1971: How to cut xray dose, 50
 1999: Memoir, with Ken W. Peterson, 50
 Morgan (Russell), radiologist: 1959 warns of "serious
 health problems" from "undue radn exposure," 32
 Morgan (W.F.) 1996: Genomic instability, 533, 534
 Morris (N.) 1984: How to cut xray dose, 23
 MortRate = age-adjusted mortality rate/100K pop'n, e77
 Age-adjusted vs. age-specific MortRates, e83-84
 This study rests on age-adjusted MortRates among
 130-250 million persons, 5, 14
 Cancer MortRates affected by radn-exposures decades
 earlier, 32, 52, 108, 212, 356
 MortRate trends, cancer, 118, 496-498, 504-506
 Grew more similar, among the Census Divs, 511
 Two organs having same xray history can develop
 opposite MortRate trends, 441, 497
 MortRate trends, IHD, 287-288
 Age-adju MortRates are affected by changes in popu-
 lation's underlying health and medical care, 499
 Quality of year-1900 data is dubious, 498
 Mosaics, mosaicism, e325
 Moss (Ralph) 1975: History of chemotherapy, 509
 "Most menacing mutagen to which people are routinely
 exposed" may well be medical radiation, 343
 "Mountain of evidence," 15, 20, 513
 mrem = milli-rem, e518. 0.001 rem. 10⁻³ rem.
 mSv = milli-sievert, e518. 100 milli-rems.
 Muhlestein (J.B.) 1996: Infection & IHD, 309-310
 Muirhead (Colin): NRPB rejects threshold, 527
 Muldoon (M.F.) 1990: Side-effects, lipid-lowering, 319
 Muller (Herman) 1927: Heritable mutations fr radn, 31
 Multi-step model of carcinogenesis:
 BEIR 1990, initiation & promotion, 114, 376
 Gofman, inherited mutation insufficient, 3, 92
 Nowell, genomic instability, 534, 536
 Rothwell 1993, multi-mutation, 3
 Trosko 1980, initiation-promotion, 330
 UNSCEAR 1993, multi-mutation, 526
 Add'l entries: Co-action. Cancer etiology.
 Munoz (N.) 1994: Infection & stomach cancer, 435
 Munro (J. Michael) 1988, with Ramzi S. Cotran: 302,
 303, 305, 306, 307, 317, 318, 331, 338, 340, 349
 Respect for Benditt monoclonal hypothesis, 331
 Equilibrium concept of lipid accumulation, 318
 Thickening of intima, 338. Fatty streaks, 338
 A key etiologic clue: Localization of plaques, 349
 Murata (K.) 1986: Composition of plaque, 303
 Mustafa (A.A.) 1985: How to cut xray dose, 23
 Mutations, e38. Permanent and cumulative nature, 9,
 12, 20, 38, 39, 519
 Please see next column.

Mutations (continue):

- Distinct from temporary damage, 39, 45, 330, 331, 340, 527, 531
- All types inducible by ionizing radn, 9, 40, 526, 528, 535, 536
 - Please see: Double-strand breaks. Doubling dose.
- Dose-response detectable decades later, 50
- Single track can induce consequential mutation, but far from certain that it will, 8, 45, 522, 526, 527, 536
- Mutation can occur at inconsequential sites, 39, 49, 340
- Variable sites, variable consequences, 92, 341-342
- Harmful mutation does not always kill a cell, 2, 8, 39, 536
- Mutated cells can gain proliferative advantage, 8, 16, 330, 340, 341, 534
- "Most menacing mutagen" & routine exposure, 343
- Inherited (vs. "acquired") mutations, e92. 3, 8, 340, 342, 496, 520
- MX Model of dose-response, e93
- MX + C Model of dose-response, e96-97
- Myocardial infarct (MI), heart attack, e276
- Myocardium, e276, e599
- Myrden (J.A.) 1969: Cancer from few tracks/cell, 523

N

- NAS 1956: Report on biological effects of radn, 32
- NatCtrHS 1980: Age-adju USA MortRates 1980, 79, 224, 279
- NatCtrHS 1993: Age-adju IHD MortRates 1993, 279
- National Academy Sci, 32, 41. Pls see: Natl Research.
- National Cancer Institute (USA), e41. Pls see: NCI.
 - Role in early smoking-health inquiry, 361
- National Center Health Stats: Described in Ref. List.
 - Exemplary policy of helpfulness, 79
 - Achieves database consistency, 81
- National Council Radn Prot: Described in Ref. List.
- National Heart Institute:
 - 1950: Sponsored "Cooperative Study of Lipoproteins and Atherosclerosis," 545
 - 1956: A sponsor of smoking-health inquiry, 361
- National Radiol Protection Bd (UK). Pls see: NRPB.
- National Research Council, 114. Please see Ref. List.
- National security, entangled w radn health science, 31
- Native states of lipoproteins, 311, 312, 313, 315, 539, 561
 - Evidence that Sf 6 and Sf 13 lipoproteins have discrete identities, 334
 - How measurement in native states can insure against therapies which convert non-atherogenic into atherogenic types of lipoproteins, 561
- Natural background radiation, e520, including dose.
 - Mentioned: 50, 55, 210, 340, 342, 351, 519
- NCI 1990: "Cancer-causing agents include xrays," 41
- NCI 1998: Health effects of cigars, 362-363; Use, 374
- NCRP 1980, 47. Rise in exams/year, 34. Leveling-off of per-rad risk at high doses, 43, 520
- NCRP 1984: Cigarette smoke delivers alpha radn, 362
- NCRP 1986: Ways to cut mammography dosage, 23
- NCRP 1987: Largest sources of voluntary radn, 536
- NCRP 1989: Per capita xray dose, 12, 33, 34. Age & dose, 37. Ways to cut xray dose, 23, 35, 36.
 - True dose vs model dose, 33. Angioplasty dose, 36, 600. Largest sources of voluntary radn, 536.
 - In 1964, est 580 xray exams per 1,000 pop'n, 611
- NCRP 1989-b: Promptly lethal dosage, 520, 531
- NCRP 1990: Dicentrics (frequency) as a standard, 47
- Neamiro (E.) 1983: Ways to cut xray dose, 23
- Necessary co-actor, e3, e4, e7, e114, e495
 - Please see: Co-action.
- Needles, sometimes guided by xrays, 9, 35
- Negative Constants, 112, 113, 212, 213, 219, 399
 - Male Respiratory-System Cancers, 393, 399-404
 - Male Urinary-System Cancers, 447, 452-454
 - Male Buccal-Pharynx Cancers, 469, 474-476
- Negative (inverse) correlations, e99, e105
- Negative X-coef means downward slope, 13, 99, 225
- Nelson (Gary), valued member of the Donner group, 542. Special focus on the phospholipids.
- NeoNatal Intensive Care Units, 35
- Nephrotic syndrome: HDL low, Sf 0-400 high, 577
- Newlin (N.) 1978: How to cut xray dose, 23
- Nichols (Alex V.): Major scientific contributor and source of leadership in the entire Donner Lab lipoprotein research effort, 313, 513, 542.
 - Co-author of Lindgren 1955, Lindgren 1959, Lindgren 1960, and other papers in the Ref. List.
 - Nichols (Alex V.) 1957: Dietary effects on serum lipoprotein levels, 311, 315, 556, 558, 570
- Nicod (P.) 1993: On plaque-rupture, 321
- "Night vs. day" (female Genital Cancers), 162
- Nitrates & Digestive-System Cancers, 435
- Nitric oxide, released by endothelial cells, 307, 331
- Nobuyoshi (M.) 1991: Relation stenosis to infarct, 322
- Non-atherogenic high-dose radiogenic damage, e599
- Non-atherogenic lipoproteins may be inadvertently converted to atherogenic types by certain IHD therapies? 311, 561-562, 564
- NonCancer NonIHD MortRates: Negative correlation with PhysPop, 14, 233-236, 618. Graphs, 26, 236
- Non-malignant tumors, radn-inducible, 297
- Non-matching in dose-response studies, 98-99, 112, 165, 358, 367, 512, 617-620
- "Not by accident" (powerful correlations), 13, 16, 644
- Nova Scotia Study, 501, 523. Also: 48 (not named).
- Nowell (Peter C.) 1976: Classic paper on tumor evolution & genomic instability, 534, 535, 536
- NRPB 1995: Analysis of threshold (safe-dose) issue, 44, 45, 521, 527-529
 - Evidence "falls decisively" against any threshold, 45, 529
 - Evidence on radn-induced dicentrics per rad, 46
- Nuclear medicine, e35. Rising rate of exams, 35
 - Estimated annual number of exams, USA, 11
 - Organ-doses from thallium-201 heart exam, 49
- Nuclear pollution, 32, 351, 530, 536
- Nuclear Regulatory Commission: Sponsor of widely used risk/rad values, 501
- Nuclear workers accumulate mutations from minimal dose-rates, 9, 521
- Nucleotide, e537
- Nygard (O.) 1997: Plasma homocysteine & IHD, 331-332

O

Obesity: Heaviness & IHD risk, 350, 570-571, 580, 595-596

Occlusion (silent) of a vessel, 349

Occupationally-induced cancer, 3, 32, 495

Ockham's Razor, an important admonition in research, e215, e512, e514. Law of Minimum Hypotheses.

O'Connor (Egan), co-author of Gofman 1985, 51

"Office building": Evacuation leaves the edifice, 347

Oleic acid (n-9), e562. And olive oil, 563

Oliver (M.F.) 1991+1992+1997: Warnings about lipid-lowering therapies, 319, 336

Omega-3 (n-3) & omega-6 (n-6) fatty acids, e562, e563. Health effects, 563-569

Optimum ratio, n-6 over n-3 = 5:1, 568

Oncley (J.L.) 1947: Alpha & beta lipoproteins, 311

Ornish (Dean) 1990+1998: Lifestyle & IHD, 336

Orthovoltage xrays, e47, e48

Osler (Wm.) 1908: Infectious etiology, atheroscl, 306

Outlying datapoints, causes & effects, 96, 213, 399

Visual demo with real-world data: Outliers move into line, 213, 220-221

Outliers: A cause of negative Constants, 399

Outliers: Persons w very high HDL-1 levels, 588-589

Ovarian cancer & genital talcum powder, 163-164

Oxidized lipoproteins, 307, 317, 345, 569

P

p-53.

CMV product interacting with p53 protein, 308-309

Painless way to reduce cancer, IHD, 1

Palade (G.) 1956: Electron-microscope studies of endothelial vesicles, 317

Pappenheimer (J.R.) 1953: Capillary permeability, 317

"Paralytic" pessimism, 55

Parker (Herbert M.), co-author of Buschke 1942, 29

Parkes (J.L.) 1991, on Benditt hypothesis: Ref.List.

Parmley (William W.) 1997: Endothelial cells and atherogenesis, 307, 345. Plaque stabilization, 321, 345. ACE inhibitors, 351

Patel (P.) 1995: Infections and IHD, 309

Patterson (James T.) 1987: No cause assigned to 38% of deaths in year-1900, 498

Pauling (Linus) warned in 1950s about health effects of radioactive fallout, 31

"Paying the price" for weight-gain, 571

Peak year for cigarette smoking, USA, 363, 365

Peak year for IHD MortRate, USA, 287, 288

Pearson (Thomas A.) 1975+1977+1978b+1983a: Monoclonality in plaques, 326-328.

1993: On LDL & endothel-derived relaxing factor, 345

1998: Lipid-lowering in low-risk patients, 336

Pedersen (Terje R.) 1994 = Scandinavian 1994, 319.

1995: NEJM editorial on lipid-lowering, 319

Peer review, viii, 8, 52, 381, 530. Appropriate, during peer-review, to challenge papers which uncritically incorporate the safe-dose fallacy, 529

Pelvimetry, pre-delivery, 17, e30, 34, 342, 524

Penicillin's introduction, 618

Penn (Arthur) 1981a+1986+1988+1989+1990+1991+1993+1994+1996: Experimental work on mutagens in the etiology of atherosclerosis, 328, 330-331, 502.

1990: Review paper in Mutation Research, 328

Pennell (M.Y.) 1952: PhysPop data & type, 57, 58

Per capita population dose from medical radn: Why "profound uncertainty among informed people," about magnitude of post-1960 decrement, is likely to be permanent, 37-38

Number of exams (past, present) quite uncertain, 33, 609-611

Doses per exam (past, present) not measured, 33, 36, 609, 610

Downward & upward pressures on post-1960 per-capita population dose, explained, 34-35

Net effect is probably downward, 37, 624

Distinction between per-capita population dose and per-patient dose, 93-94

Perfect correlation, e12, e63, e95. Can persist while x-values rise, y values fall, 97-98

Perfect proportionality, e62, e63, e93, e97

Pericardium, e599

Per-patient dose, alike in 9 Census Divisions, 93-94, 623

Per-rad potency. Please see: Risk per rad.

Perry (I.J.) 1995: Plasma homocysteine & IHD, 331

Peterson (Ken M.) 1999: Co-author w. K.Z. Morgan, 50

Petrie (B.L.) 1987+1988: Viral etiology atheroscl, 308

Phillipson (B.E.), research on n-3 fatty acids, 563

Photofluorogram, e611

Photon, e38. The biological damage from xrays is due to the photons which never reach the film, 8

PHS 1959: Measures needed to limit radn exposure, 32

Estimated annual per capita dose, 33

PHS 1992: Multiple reference years, age-adju MRs, 82

PHS 1995: State-distribution in the Census Divs, 57

U.S. population in 1940 by age-bands, 82, 87

PhysPop values 1975-1994, 59

Breast cancer age-specific rates (1950-1993), 88

PhysPop = Physicians per 100,000 population, e5, e12.

PhysPop values by Census Divisions reflect relative magnitude of per capita population dose from medical radiation, 53-54, 499

NonCancer NonIHD analysis supports validity of of this surrogacy, 223, 514

How PhysPop reflects accumulated per capita dose, 12, 56, 61, 65, 100

Stability of PhysPop proportions & ranking over decades, by Census Divs, 61, 63-65, 356-358, 366

Tabulated non-averaged, 66, 76. Averaged, 359, 360

Merits of using PhysPops as dose surrogates, 11-12, 14-15, 54-55, 500

PhysPop history permits this inquiry, 65, 356

Pickels (Edward G.) 1942+1943: The engineering/physics genius who produced two remarkable instruments, the electrically driven analytical ultracentrifuge & the preparative ultracentrifuge, 311

"Pie-charts" of estimated per-capita radn doses, 37

Pierce (Donald A.), Radn Effects Research Foundation: 1996-a: A-Bomb Study really a LOW-dose study, 42

- Pierce (D.A.) continues:
 1996-b: Latency lasts at least 45 years, 49
 Dose-response is linear or supra-linear, 43
 Under-reporting of cancer mortality, 81
 Female genital cancers & bomb-exposure, 162
 Pierce (Frank T., Jr.), valued member of the Donner lipoprotein group:
 1952: Explained Duff's 1949 "smoking gun," 539
 1954-a: Steady-state concentrations, lipoproteins, 542
 1954-b: Hepatitis & serum lipoproteins, 543, 577
 Pifer (J.W.) 1963: Healthy babies got fluoroscoped, 29
 "Pipeline," cancer-cases in the pipeline, 91
 Pitfalls in epidemiology:
 Too many statistical operations, 15
 Failure to appreciate equilibrium, 50
 Snapshot epidemiology, 594-598
 Use of tainted databases, 54-55, 216
 Discarding established barriers against bias, 43, 546, 617
 Failure in matching, 98-99, 112, 165, 358, 367, 512, 543. Failure, in non-radn studies, to match for medical radiation, 515. Failure to match for level of medical care, 617-620
 Pitt (B.) 1995: IHD therapy, prevention, 336
 Placebo = an inactive substance designed to appear identical to an active ("real") medicine, 319, 320
 Plaque (atherosclerotic), e300.
 A "hive of activity," 339, 347. An "edifice," 347
 Localized nature requires explanation, 300, 339, 349
 Plaque rupture (or fissure) & infarcts, 321-325.
 After strenuous exercise (Black's Crack), 324
 Thrombogenic lipid core meets bloodstream, 322-323
 Nonfatal rupture & plaque growth, 321, 322, 348
 Plaque erosion, 321
 Stabilization of plaque. Please see: Stabilization.
 Add'l entry: Atherosclerosis (Features of lesions).
 Plasma is the colorless-fluid portion of whole blood.
 Serum is plasma after removal of the blood-clotting factors. When whole blood is allowed to clot, blood serum is the clear liquid which separates from it. Both plasma and serum contain the lipoproteins described by pages 310-313. "Cloudy" serum, 315
 Plasma lipoproteins: Basic data, e310, e556.
 Varieties and history, 311-313, 333, 334, 538-554
 Constant composition, or not? 542, 549, 550
 Molecules in metabolic chain, 315, 335, 542, 561-562
 Studied in their native states, 311, 312, 313, 315, 539, 561
 Diagrams of size, composition, 333
 Cholesterol-rich, triglyceride-rich, 313
 Molecular weights, diameters, 333
 "Giants," 312, 317. Size matters, 310-312, 314, 539
 Nomenclature (current): LDL, IDL, VLDL, 312
 Flotation diagrams, 2 discrete species, 334
 Concentration by age, gender, 570, e576, 596
 Fasting vs. non-fasting levels, 541-542
 Body-weight & serum lipoproteins, 569-571
 Steady-state concentrations, 316, 542
 Cases classed by types (e.g., Type II-a), 563
 Plasma lipoproteins: Lipid Hypothesis, e310, e595.
 310-316, 538-554. "Foreign bodies," 310, 338
 Please see next column.
- Plasma lipoproteins: Lipid Hypothesis (continues):
 Integrated exposure over time, 594, 595, 596, 598
 An early piece of good luck, 540
 Initial case-control studies, 540-541, 594
 First 3 prospective studies, 544-548, 579-580, 594
 Why lipid-levels only APPEARED less important at older ages, 594-598
 Once an atherogen, always an atherogen, 598
 Determination of independent atherogenicity, 314, 315, 543-544, 552-554, 586, 594
 "Not easy to do," 544
 Clinical effects of reducing plasma "lipids," 318-321, 322, 336. Please see: Stabilization.
 Retention of lipoproteins in the intima, 316-318.
 Denatured, reduced solubility, 316. Oxidation of the lipoprotein molecules, 307, 317, 345, 569
 Plasma lipoproteins: Some current controversies.
 HDL: Is HDL truly anti-atherogenic? 314, 577-585
 Small, dense LDL particles: Very bad? 586-593
 Serum triglyceride: Atherogenicity, 314-316, 555-566
 High-carbohydrate diets, 315, 558-561
 Beware of "snapshot epidemiology": Once an atherogen, always an atherogen, 598
 Obligation to determine that therapies do not convert non-atherogenic lipoproteins into atherogenic ones, 311, 561-562, 564
 Mediterranean diet, n-3 fatty acids, 566-569
 Dissent on lipid-lowering therapies, 319, 336
 How much health-benefit would accrue from retaining our age-20 weight? 571
 Plowshare Project: Peaceful use of atomic bombs, viii
 Plutonium, viii
 Pneumothorax TB therapy, e28, 48, 523, 527. Also: 501.
 Policies in this monograph:
 Show steps from raw data to results, 2
 Adjusted data: Show "before" & "after" values, 367
 Significant figures and trailing digits, 83
 Polonium-210, alpha-emitter from cig smoke, 329, 362
 Populations, 1910-1990, of Census Divisions, 75
 Poretti (G.) 1985: How to cut xray dose, 23
 Portioli (R.J.) 1963: Heart damage & radn therapy, 601
 PostCABG 1997: Trial of IHD therapy, 336
 Postponing (vs. preventing) disease, 1
 Pravastatin 1993: IHD therapy and prevention, 336
 Prediction of National MortRates by PhysPop dose-response 20 years earlier, 214, 296, 513
 Predisposition (inherited). To cancer, 3, 51, 92, 164-165, 496. To IHD, 351
 Pregnancy: Fetal irradiation was quite common, 17, 30, 342
 Pre-natal xrays: Few tracks/cell nucleus, 524
 Prentice (R.T.W.) 1965: Heart damage by radn, 601-602
 Preston (Dale L.) 1997: "Simply no way" that A-Bomb evidence suggests a threshold for solid cancers, 46
 Prevalence (of a disease), e277
 Prevention of disease: A chief reason to study causes, 1, 19, 20, 310
 Secondary prevention = preventing the recurrence or progression of an existing disorder.
 Primary ionization track, e38. Please see: Track.
 Progression of atherosclerotic lesions, 303, 318, 319, 321, 322, 346, 347, 348, 349, 352, 594

Prokopczyk (B.) 1996+1997: Papilloma virus needs co-actor to cause cervical cancer, 165
 Proliferative advantage from mutation, 8, 16, 330, 340, 341, 534
 "Promiscuous" use of radiotherapy (Dewing 1965), 30
 Promotion, in carcinogenesis, 3, 114, 330, 376
 Trosko on membrane-Ca++ regulation, 330
 Properzio (W.S.) 1985: How to cut xray dose, 23
 Proportionality, e61, e62, e63, e93. R-squared reflects deviation from perfect proportionality, 64
 Prospective studies, e544, e580, e595.
 Evidence of what precedes what, 544
 Selective pressure, 580
 "Gold standard," 213. Dose-response, 513
 Size of such studies matters, 15, 213, 501
 This monograph represents one of the largest prospective studies imaginable, 214, 216, 501
 Prediction of Natl MortRates by PhysPop dose-response 20 years earlier, 214, 296, 513
 Early prospective studies on plasma lipoproteins and IHD: Coop, 545-546. Framingham, 546-547, 579-580. Livermore, 547-548, 580.
 Lipid-lowering trials, 318-321
 Generic hazard of "snapshot" epidemiology, 594-598
 Prosser (J.S.) 1983: Low-energy radn & mutations, 46
 Prudence, in medicine, 20, 362 (Surgeon General)
 PTCA = Percutaneous Transluminal Cardio-Angioplasties.
 Associated xray dosage, 36, 600
 Number per year, USA, and age of patients, 36, 37
 Public Health Service, 32, 35, 57, 58, 82, 361, 609
 Surgeon General is PHS chief, 32, 361. Pls see: PHS.
 Purrott (R.J.) 1977: Radn-induced mutaton, 46

Q, R

Quality-assurance in xray facilities, 23, 35
 Quinn (T.G.) 1992: IHD therapy and prevention, 336
 R.
 R = correlation coefficient, e12, e63. R is always a higher number than R-squared (whose max = 1.0).
 Rad defined, e517. Please see: Risk per rad.
 Radford (Edward P.), Chair of BEIR-1980 Com'tee, 40.
 1964+1977: Polonium-210 in cigarette smoke, 362
 1982: Ionizing radn = most consistent carcinogen, 40
 Radiation, defined. Please see: Ionizing radiation.
 Radiation Effects Research Fdn: Described in Ref.List.
 Radiation-induced cancer, defined, e3, e356
 Radiation therapy for cancer. Pls see: Radiotherapy.
 Radio-isotope = radio-nuclide. Please see below.
 "Radiomaniacs" in early xray usage (MacKee 1938), 28
 Radio-nuclide = a radioactive atom which will decay by emitting some type of ionizing radiation, 35
 "Radio-phobia," 17
 Radiotherapy for cancer, 1, 2, 9, 508-509, 520, 600
 Some dose-levels, 600, 601, 605
 Cause and treatment by the same agent? 2
 Radn-therapy tried also for benign disorders, 28, 30
 Radium & its daughters: Gamma rays, 30, 51, 522
 Alpha emissions, 32
 Radium, a radioactive gas. Co-actor with smoking, 4.
 Exposure of uranium miners, 32. Radon adds to natural background dose, 520. Evaluated by IARC, 41

Rank order, behavior over decades.
 Census Divisions by PhysPop values, 66, 359
 Men by "snapshot" lipoprotein levels, 597-598
 Rapp (J.H.) 1991: Direct influence of dietary fatty acids on fatty acid of lesions, 569
 Ravenskov (U.) 1991+1992+1993+1994+1995a+1995b:
 Skeptic about benefits of lipid-lowering, 319, 336
 Rayer (P.) 1823: Inflammation & atherosclerosis, 305
 "Reality check" on the free-radical argument, 531
 Reardon (M.F.) 1985: Triglyceride & IHD risk, 565
 "Reasonable standard of biomedical proof," 46, 521, 525
 Regression analysis, e12, e94
 How it is done, 94, 108-110
 Equation of best fit, 94, 110
 Graphs: Line of best fit, 94, 110, 115, 117
 Reversal of x,y designation doesn't chg R-sq 64, 359
 Regression of atheroscl lesions, 321, 322,, 347
 Relative Biological Effectiveness (RBE), e518
 Relative weight = ratio of actual weight over "ideal" weight for a particular height and gender, 570.
 Here, relative weight tables were prepared by Metropolitan Life Insurance Co.
 Rem, e518. One centi-sievert (cSv).
 "Remarkable finding," how death-rates relate to physician-density, 296
 Renaud (Serge) 1995: Lyon Diet Heart Study, 556, 566, 568, 569.
 1996: Why the study had to be stopped early, 567
 Repair-system of cell for genetic damage: 44-45, 521
 Capacity not saturated by high-dose radn, 46, 523
 Time for repair = a few hours, 523, 527
 Least possible challenge to repair-system = 1 ionization track, 44, 45, 522, 523, 524, 525, 527
 Some lesions defy perfect repair, 8, 38, 39, 40, 45, 524, 527, 528-529, 532
 "Troublesome trio," e524. LMDS, e528
 Unrepaired damage = mutation, 38, 39, 340, 531
 Repair of single-strand DNA damage, more successful than repair of double-strand breaks, 528, 529
 Perfectly repaired damage, no consequence, 342, 532
 Mutation of the repair-genes themselves, 39, 534
 RERF = Radiation Effects Research Foundation, e41
 Respiratory-System Cancers: Post-1940 impact of smoking, 366-367, 368 (Box 2), 369,, 371 (Fig 48-B)
 Response to Injury Hypothesis, e306. 306-310
 Add'l entry: Endothelial cells.
 Restenosis, e308
 Retroactive changes in databases, 43, 546
 Retzlaff (B.M.) 1995: Dietary carbohydrate effect, 560
 Rheumatic fever, after anti-biotic revolution, 618
 Rice (Jerry M.): IARC on radiation, 41
 Richardson (P.D.) 1989: Thin fibrous caps, 323
 Riches (A.C.) 1997: 14 rads alpha radn corresponds with about 2 ionization tracks per cell, 529
 Richter (Elihu): AAAS Breast Cancer Symposium, 51
 Ricketts (W.E.) 1951: Xray therapy of peptic ulcer, 31
 Ridker (Paul M.), 300. 1997+1998: C-reactive protein predicts first infarct, 306. 1999: Homocysteine 331
 Riemersma (R.A.) 1989: Anti-arrhythmia effect of n-3 (omega-3) fatty acids, 569
 Rifkind (Basil U.), co-author of Gordon 1989, 578
 Rimkus (D.) 1984: How to cut xray dose, 23

- Rimm (E.B.) 1993: Anti-oxidants and IHD, 569
 Rings (chromosomal), radiation-inducible, 5, 7, 39
 Ringworm of scalp: Xray therapy used, 30, 524
 Risk per rad:
 Reasons for uncertainty, 11, 48, 500, 515
 BEIR 1990 admits some low-dose studies show risk per rad "substantially" above its own estimate, 11
 BEIR 1990 admits defeat in explaining 6-fold diff in apparent risk/rad for breast cancer, 48
 Evans 1986 admits any risk/rad est is uncertain, 501
 Alteration of per-rad risk by co-actors, 4, 90, 98, 114, 376-377, 483, 497, 499, 623. How: 377, 497
 Inclusion of high-dose data will cause underestimated risk/rad at low doses, 43, 520
 Variation of per-rad risk by organs, 377
 Per-rad risk & X-coefficient, 499. Pls see: X-Coef.
 Risk versus rate: Individuals vs. group, 46
 Roback (G.) 1990+1994: 75. Please see AMA 1990+1994.
 Roberts (W.C.) 1972+1973+1974+1975: Composition of plaques at autopsy, 604
 1978: Rate of autopsies in 1950, 81
 1981, co-author of Brosius 1981, 605
 Rocky Mountins: Target of peaceful atom-bombs, viii
 Roentgen, a dose-unit (R, or r), e517
 Roentgenoscopy means fluoroscopy, e28, e29, e610
 "Roentgen Tragedy," 499
 Roentgen (Wilhelm) 1895: Discovery of the xray, 9, 27, 77, 210, 212
 Rohl (A.N.) 1976: Asbestos-contaminated talc, 163
 Ron (Elaine) 1991: Xray-induced skin tumors, 297.
 1995: Gamma-induced benign GI tumors, 297
 Rosano (G.M.C.) 1993: Estrogen & plasma lipids, 352
 Rosenberg (Harry) helpful at Natl Ctr Health Stats, 79
 Rosenfeld (M.E.) 1987+1987b: Early lesions develop at sites of intact endothelium, 307.
 1990: Oxidized LDL and endothelium, 307
 Rosenson (R.S.) 1998: IHD therapy & prevention, 336
 Rosenstein (M.) 1979: Reducing size of xray beam, 34
 Ross.
 Ross (Russell) 1973+1976+1976b+1977+1981+1986+1993:
 "Response to endothelial injury" hypothesis, 306-307
 Early lesions occur at intact sites, 307
 Atherosclerotic lesions, 302. Oxidized lipoproteins, 317, 318. Platelet-derived growth factor & cell proliferation, 326-327. Fatty streaks, 338
 Rossouw (J.) 1990: NonIHD death & lipid-lowering, 319
 Rothwell (N.) 1993: Multiple mutations/cancer cell, 3
 Rowley (K.) 1987: How to cut xray dose, 23
 Royal College 1983: Smoking in Britain, 361, 363, 370
 R-squared value, e12, e63, e64, e95
 Maximum value = 1.00, 95
 Summary of R-squared findings for 1940, 1950, 22
 Rubin (E.) 1963: Heart damage from radiation, 601
 Rubin (L.) 1954: Mononucleosis & lipoproteins, 543
 Rubins (H.B.) 1995: Variations in plasma HDL conc, 579
 Rudel (L.) 1986: Gel filtration of lipoproteins, 564
- S**
- Sacks (F.M.) 1996: Pravastatin trial, 320, 336
 Safe dose = risk-free, threshold dose, e8, e44, e521, e526, e529
- Safe Dose (continues):
 Evidence against any safe dose, 44-46, 521-529
 Safe way to reduce cancer & IHD, 1, 18, 20
 Sandker (G.N.) 1993: Ratio n-6/n-3 fatty acids, 568
 Sasaki (M.S.) 1975: Radn & chromosome mutations, 38
 efficient chromosome-breaker, 38
 Scandinavian 1994: IHD therapy, 319, 336 (Pedersen)
 Scatter of datapoints, 63, 64, 92, 110
 Scatter of photons, 600
 "Schools" over what initiates atherogenesis, 305
 Schuler (G.) 1992: IHD therapy and prevention, 336
 Schull (Wm.): A-Bomb Study & IHD, 501-502
 Scoliosis = curvature of spine, e17. Immense cut in associated xray dose is demonstrated, 17-18
 S.E.
 S.E. = standard error, e12, e95
 X-coef/SE reflects reliability of slope, 12, 95
 Seaborg (Glenn T.) 1972: History of U-233, viii.
 1993: AEC treatment of dissent, viii, 533
 Secondary prevention. Please see: Prevention.
 SEER 1997, 187. Changes in US cancer-rates, 506
 Segal (A.J.) 1982: How to cut xray dose, 23
 Segaloff (A.) 1971: Co-action, radn & estrogen, 114
 Selective pressure & prospective studies, e580-581
 "Select themselves out," 296
 Serum. Please see: Plasma.
 Sf unit: Identifier of lipoproteins, e312, e335, e541.
 One Sf unit represents a flotation rate of $1 * 10^{-13}$ cm/second/dyne/gm. Since the analytical ultracentrifugation of low-density serum lipoproteins is carried out under specified physical conditions (lipoproteins in a sodium chloride solution of density 1.063 gm/cc at 26 degrees C.; 52,640 RPM at a radius of 72.5 mm from the center of rotation to base of the cell), the flotation rate for a particular lipoprotein species is a physical constant characteristic of the species, after adjustment for concentration effects (Gofman 1954-a, p.414-415).
 Std Sf, e541. And 1956 Coop Study, 545
 Shah (K.V.) 1997: Papilloma virus & cervical canc, 164
 Shameful to have cancer in family (a belief), 498, 510
 Shapiro (J.) 1990: Closeness, roentgens & rads, 517
 Shepherd (J.) 1995: Pravastatin study, 319, 320, 336
 Shimizu (Y.) 1987+1988: Linear vs. supralinear dose-response, A-bomb-induced cancer, 42
 1992: A-Bomb Survivors & noncancer rates, 501-502
 Shlien (B.) 1977: Annual rate of xrays by age, 616
 Shope (Thomas) 1996+1997: Fluoroscopy. Big increase in use since 1977; ways to reduce dose, 35-36
 Shore (Bernard): Valued member of Donner group, 542
 Pioneer in recognizing & characterizing lipoprotein lipase.
 Shore (Roy E.) 1993: Radn-induced benign tumors, 297
 Shore (Virgie) 542. "Donner Dinner" in honor of her & F. Lindgren: Please see Gofman 1990-b in Ref. List.
 "Shortcut which fogs the lens," 316, 352
 Shoveling snow & heart attack, 324
 Shrivastava (P.N.) 1980: How to cut xray dose, 23
 Sievert (dose-unit), e518. 100 rems.
 Significant figures & trailing digits, this book, 83
 Simonton (John H.) 1951: Macrophage migration NOT the source of lipid-filled foam cells, 542

- Simopoulos (A.P.) 1998: Dietary fatty acids, 563, 564
 Singh (R.B.) 1992a+b: IHD diet-study like Lyon, 568
 Single-cell origin of cancer, 325, 526, 529, 534
 Single ioniz track can cause mutation. Pls see: Track.
 Single-strand DNA damage & repair, 528, 529
 Skin cancer in early radiologists, 32
 And in patients xray-treated for ringworm, 297
 Skin disorders, treated by xrays, 30-31
 Skin injury by xrays, 28, 606-607. Cancer: 32, 297
 Slattery (M.L.) 1989: Cig. smoke & cervical ca, 165
 Slope of the best-fit line, 64, e94
 Reliability is indicated by ratio (Xcoef/SE), 96
 Slyper (A.H.) 1994: LDL and atherosclerosis, 586
 "Small, dense LDL particles," 313, 586-593
 "Small numbers problem," e107, 162, 169, 181
 SMC = Smooth Muscle Cell, e340
 Smith (Elspeth) 1967+1972+1974+1975+1976+1977: Entry, retention, egress of lipoproteins, 317-318.
 1977: "Infinite variety" of athero lesions, 300, 302
 Smith (G.) 1992: Lipid-lowering, nonIHD death 319, 336
 Smith (Karen) 1997: CMV infection & restenosis, 309
 Smoke's primary lung-carcinogen is alpha radn? 362
 Smoking-adjusted MortRates, method, 378-381, 624
 "Smoking guns" (observations having bigger meanings):
 1949: Cholesterol-fed diabetic rabbits, 539
 1952: Xanthoma regression, 543
 1981: Higher cancer-rate & higher PhysPops, 50, 52
 1999: Strong dose-response, PhysPop & IHD-rate, 337
 1999: Cancer & IHD relationships with PhysPop are so similar, and so unlike NonCancNonIHD, 298, 337
 Smoking of cigarettes. Please see: Cigarette smoking.
 Smooth muscle cells of arteries, e299, e306
 SMCs located in arterial media, 299
 SMCs located in fatty streaks, 338
 SMCs located in plaque, 301, 302, 303
 SMCs crucial to fibrous caps, 323, 324
 New view of their role in acute events, 323-324
 Functions of normal SMCs, 305, 340
 Mutated, dysfunctional clones of SMCs, e339, 341-342
 Expanding plaque may acquire normal SMCs too, 347
 "Snapshot epidemiology," generic hazard, e595, e598
 Snapshots in pathologic examinations, 300
 Snow shoveling & heart attacks, 324
 Solid cancers, e42
 "Spectacular" correlations in the data, 12, 13, 272
 Speir (Edith) 1994: Viral protein & p53, 308-309, 331
 Spodick (D.H.) 1959: Heart damage & radn therapy, 601
 "Spontaneous" cancer-rate, includes xray-induced, 50
 Srinivasan (S.R.) 1972: Lipid-retention, intima, 318
 Stabilization of plaque against rupture, 321, 324, 325, 345, 569. Libby: Integrity of fibrous cap determines stability, 323. Unified Model and lipid-lowering benefits, 346-347, 353
 Stamler (J.S.) 1996: Homocysteine & nitric oxide, 331
 Stampfer (Meir J.). 1992: homocysteine & IHD, 331.
 1993: Vitamin-E vs. IHD, 569.
 1996: Triglyceride controversy, 316. Small, dense LDL particles and IHD risk, 586, 587, 592
 "Standard Million Population, 1940," e83, 87
 Standard Sf Unit, e335, e541
 Stanton (R.) 1983: How to cut xray dose, 23
 "Startling fact" described by Benditt, 326
 Stary (Herbert C.) 1987: Lipid pool & foam cells, 318.
 1992: Compensatory remodeling of wall by plaque, 303
 1994+1995: Stages, types of atheroscl lesions, 301
 Stather (John W.): NRPB rejects threshold, 527
 Statins: Lipid-lowering pharmaceuticals, e319
 Three trials described, 319, 320. Some others, 336
 Statistical operations: Many layers can lead to unreliable results, 15
 Statistical significance, 43
 R-squared value = 0.3 or higher, 95
 X-Coef/SE (ratio) = 2.0 or higher, 12, 22, 96
 P-value = 0.05 or lower, 162
 Sig. correlation, 1921 PhysPops & 1940 cancer MortRates, 211, 214
 Sig. correlation, 1931 PhysPops & 1950 IHD MortRates, 281, 290
 Stat. significance & female genital cancers, 161-163
 Graph of a NON-significant dose-response, 167
 Sig. & the "small numbers problem," 107, 162, 169
 Steepness (visual) of best-fit line varies with the scale of a graph, 110, 225. Absolute steepness is measured by X-Coef, 213, 218, 220, 221
 Steer (A.) 1973: Pre-death diagnosis vs. autopsy, 81
 Steinberg (D.) 1991: Oxidized LDL & endothelium, 307
 Steinbrecher (U.P.) 1990: OxLDL & endothelium, 307
 Sterman (M.B.) 1972: Endothelial injury, 306
 Stenosis (narrowing of lumen), by percentages, e303
 Occlusion (silent), 348
 Evidence destroys dogma that the most stenotic plaques are the most dangerous, 304, 322, 347-348
 Negligible stenotic regression is associated w the big clinical benefits of lipid-lowering, 321, 345, 347.
 Stents (radioactive) to prevent re-stenosis, 35
 Sterilization of cells by radiation, 2
 Stewart (Alice) 1956+1958+1970: Cancer from very few ionization tracks per cell-nucleus, 524
 Stewart (J.R.) 1967+1984: Heart damage by high-dose radiation, 601-603, 606, 607
 Stewart (William H.) 1960: PhysPop data, 58
 Stigma, against cancer in the family, 81, 498, 510
 Stochastic, non-stochastic, e502
 Stomach cancer. Diagnostic difficulty, 22, 81, 274
 HelicoBacter pylori as a possible co-actor, 435
 Storey (Alan) 1998: Inherited risk, cervical canc, 165
 Straume (T.) 1995: Xray more mutagenic than bomb 46-47
 Strisower (Beverly). Please see Donner Laboratory.
 Strong (J.P.) 1966: Internatl Atheroscl Project, 321
 Structural chromosome mutations, e39, e533.
 Ionizing radn is a well-established cause, 528, 533
 Very low doubling-dose, 39. Please see: Chromosome. And: Ionizing radn. And: Mutation.
 Suleiman (O.H.) 1992: Correct film-processing would reduce xray dose, 35
 Sulkin (N.M.): How do lipids get into plaque? 542
 Sullivan (C.) 1986: Regression analysis by LOTUS, 94
 Sullivan (D.R.) 1986: Dietary fish oil & lipoproteins 564
 Sulzberger (M.B.) 1952: Xray therapy of dermatoses, 90
 Suntharalingham (N.) 1982: Unpredictable doses, 33

Supra-linear dose-response, e42. Observed in A-Bomb Study, 42, 43. Not expected from PhysPop, 93-94
 SurgeonGen 1964: Cigarettes & lung-cancer, 361-362
 Co-actors in single case of disease 3, 283, 362, 495
 Surgery and xrays. Use of xrays is increasing, 2, 9, 28. List of high-dose surgeries, 36
 Past usage, 29, 30.
 Surgery: Post-surgical infection, 618
 Surprise when strong, positive PhysPop-IHD correlation was uncovered, 13, 16, 233
 Svedberg (The) 1940: Great Swedish physical chemist who pioneered ultracentrifugation, 335
 Syphilis: Mid-century revolution in treatment, 618

T

Talcum-powder (genital) & ovarian cancer, 163-164
 USA: 28% to 51% of women use it, 164
 Tamplin (Arthur R.), viii. A very valued colleague in some of the work leading to both Hypothesis-1 and Hypothesis-2. Co-author of several papers in the Reference List.
 Tamponade, acute heart-compression, e602
 TaskForce 1994: Lowering of serum cholesterol 319, 336
 Taylor (Kenneth W.) 1979+1983: Demonstrated how to cut xray dose to 33% in radiologic offices, without loss of image-quality & without expensive purchases, 51
 T-cells can inhibit collagen synthesis for cap, 323
 Tchernof (A.), co-author of Lamarche 1997, 586
 Temin (H.) 1988: Mutation-sequence in tumor cells, 535
 Terkel (Studs) 1995: AEC effort to stifle dissent, 533
 TG = Triglyceride, e562
 Thallium-201 heart exam: Radn doses, 49
 Thermoluminescent dosimeter, simple & low cost, 18
 Thom.
 Thom (D.H.) 1992: Half of IHD still unexplained, 337
 Chlamydia pneumoniae & IHD, 309
 Thomas (W.A.) 1963+1979+1983: Studies of monoclonality in atherosclerotic lesions of aorta, 326, 328
 Thompson (P.D.) 1997: Exercise & plaque rupture, 324
 Thorium, thorotrast, & liver cancer, 32
 Threshold dose-level = risk-free safe level, e43, e521, e526, e529
 Evidence from 3 similar reports that no threshold exists for radn mutagenesis, 44-46, 521-529
 Also: A-Bomb Study suggests no threshold, 43, 46
 "Thrombogenic Lipid Core" under the fibrous cap, 323
 Thrombus (blood clot) e275. And acute IHD events 275
 Thrombosis triggers large share of acute IHD events, 275, 321-322, 324. Nonfatal thrombus can increase plaque-size, 321, 322, 352
 Thymus gland = a gland located under the breast plate.
 High-dose thymus irradiation before tonsils removed, 28
 Thyroid cancer following thymus irradiation, 32
 Thyroid hormone & plasma lipoprotein levels, 352
 "Tight" dose-response, e10
 TIMPS, e340. Protects extracellular matrix.
 Tissue factor, e322-323. Potent pro-coagulant.
 TLD = ThermoLuminescent Dosimeter, e18
 Tlsty (T.D.) 1993: Genomic instability & canc 533, 535
 Tobacco 1976: Britain's cigarette history, 370

Tobacco consumption (annual), pounds/capita, 374
 Tonomura (A.) 1983: Chromo mutations accumulate, 39
 Track (ionization), e38, e45, e525
 Single track can cause consequential mutations, but far from certain that it will, 8, 45, 522, 526, 527, 536. Single alpha track, 529.
 Number of tracks per cell-nucleus = the relevant way to define lowest possible dose & dose-rate, 45, 521, Gofman. 525, UNSCEAR. 527, NRPB.
 Conversion, rads to tracks/nucleus, 45, 522, 523.
 Separate estimate by UNSCEAR, 525
 Track analysis + epidemiology, combined, settle the threshold issue, 44. UNSCEAR on combination, 525
 Tracy (R.E.) 1965: LDL retention in intima, 318
 Trailing digits & significant figures, this book, 83
 "Trail of cancer-consequences," (each annual dose) 210
 Translocations, radiation-induced, 5, 7, 39
 Treasure (C.B.) 1995: Why lipid-lowering "works," 345
 Triglyceride (TG), e562. Transport in blood, 310, 556
 Triglyceride-rich lipoproteins, e313, e333
 Controversy on independent atherogenicity of "TG", 314-316, 544, 555, 565
 Affirmative view on Sf 20-100+, 314-315, 316, 561
 Affirmative "View from Framingham," 565-566
 High-carbo diets raise Sf 20-400, 315, 559-560, 573
 High-carbo diets raise "total TG," 560
 Health hazard of reliance on "Total TG" measurement, 311, 315-316, 561-562, 564
 "Trio Sequence" of Census Divisions, 61, e66, e357, e366, 369
 Tritium ~ 5-fold more mutagenic than bomb radn, 47
 Trosko (J.E.) 1980: Proposed that mutations are necessary but not sufficient for atherogenesis, 329-330. Radiation and smoke as mutagens, 330, 350
 "Troublesome trio" for repair of gene-damage, e524
 Tuberculosis: Pneumothorax therapy, e28, 48, 523, 618
 Mid-century revolution in treatment, 618
 Tucker (J.D.) 1994: Chromo mutations accumulate, 39
 Tumors (benign) induced by radiation: evidence, 297
 Tyndall (D.) 1987: How to cut xray dose, 23

U, V

Ulcers: Some deaths reported as ulcer, truly stomach cancer? 22, 81, 274. Ulcers & radiotherapy, 30, 31
 Ultracentrifugation of plasma lipoproteins, 311
 Flotation vs. sedimentation, 333. Sf unit measures speed of flotation, 312, 335.
 Flotation diagram & movement of inverted peaks, 334
 The Svedberg, pioneer of the instrument, 335
 Ultracentrifugation vs. chemical analysis of the plasma lipoproteins, 316, 544, 553, 554, 564
 Underprocessing of xray film: Increases xray dose, 35
 Unified Model of Atherogenesis & Acute IHD Death.
 Intersection of lipoproteins & mutations, 337-343
 Numerous genetic pathways to dysfunction, 341
 "Smoking Gun": Strong PhysPop-IHD dose-response, 337
 Why lesions are very localized, 339
 Why only certain plaques are rupture-prone, 342
 Why lipid-lowering cuts acute events, 346, 347, 353
 This model consistent w. other risk-factors, 345-353
 Please see next column.

Unified Model of Atherosclerosis (continues):

- This model consistent w benefits of Medit Diet, 569
 Pre-xray IHD: Natural radn & nonradn mutagens, 342
 Uniquely potent mutagen: Ionizing radn 8, 38, 515, 532
 Unmatched co-actor: Cigarette smoking, 358, 366-367
 UNSCEAR = United Nations Sci Comtee on Effects Atomic Radn, e32. Slash separates page from paragraph, 525
 1958: Report during fallout furor, 32
 1982: Co-actors alter per-rad potency, 114, 377
 1986: Initial latency of leukemia < 5 years, 91
 1988: Radn can induce cancer in most organs, 40
 1988: List of ways to cut xray dose, 23
 1988+1993: Number of xray exams per capita is proportional to PhysPop, 12, 54.
 1993: Threshold would demand perfect repair 45, 527
 "Significant radiol. impact" of diag. xrays, 17
 Xray exams: Annual numbers of med + dental, 11
 1994: "Adaptive" responses to radiation, 617
 Upper G.I. Exam: Dose and exposed organs, 49
 Upton (Arthur C.), Chairman of forthcoming threshold study for MCRP, 529
 Uranium decay-series, 329. Discovery of U-233, viii
 Urbanization at mid-century, 511
 Van de Wal (A.C.) 1994: Plaque stabilization, 325
 Verhoef (P.) 1994: Homocysteine & vasc. disease, 331
 Viruses. As carcinogens, 164-165, 210, 496
 As atherogens, 307-309
 Vivo, vitro. Please see: In vivo, In vitro.
 VLDL (Very Low-Density Lipoproteins), e312

W

- Wagner (R.S.) 1976: How to cut xray dose, 23
 Waller (B.F.), co-author of Brosius 1981, 605
 Ward (John F.), Research Professor of Radiology, UnivCalif LaJolla, & a leading authority in study of how radn interacts with cells, 38, 528, 532.
 1985+1985b+1988+1990+1991a+1991b+1994+1995, 532.
 Warren (Shields) 1942: Effects of high-dose radiation upon heart & small blood vessels, 606-607
 Waters (D.) 1994: IHD therapy & prevention, 336
 Watts (G.F.) 1992: IHD therapy & prevention, 336
 Webster 1954: "Ideal" data, e62
 Webster (M.W.I.) 1990: Silent occlusions, 348
 "We don't DO that anymore!" 37
 Weight fluctuations & lipoprots, 569-571, 595-596
 Weiss (P.) 1998: Another Face of Entropy, 100
 Well-baby check-ups with fluoroscopy, 29, 31, 610
 Wells (H.G.) 1923: Clinical diagnoses vs. autopsy, 81
 West Scotland Pravastatin Study, 319-320
 "What if..." speculations, 112
 Whites-only analysis, 211, 218, 295
 WHO = World Health Organization (United Nations).
 WHO 1958: ICD system, e80, e84, & Ref. List.
 WHO 1995: Thyroid canc latency < 5 yr after radn, 91
 WHO 1996: Xrays listed as a cause of cancer, 41
 Helicobacter pylori, co-actor in stomach canc, 435
 Hepatitis virus, a co-actor in liver cancer, 496
 "Whole new ballgame" begins, 339
 Wiatrowski (W.A.) 1983: How to cut xray dose, 23
 Wilcox (J.N.) 1989: Tissue factor & thrombosis, 323

- Winklestein (W., Jr.) 1990: Smoking & cervical ca, 165
 Winters (T.H.) 1982a+b: Polonium-210 & cig. smoke, 362
 Witztum (J.L.) 1991: Oxidized LDL, 569
 Wocho (J.F.) 1977+1979: Xray dose differs by place 33
 Wolbach (S.B.) 1909: Delayed, progressive vascular damage by xrays, 607
 Wolfman (L.) 1986: Rising sales of xray film, 34
 Wong (F.L.) 1993: Bomb-induced benign tumors, 297
 World Almanac 1991: Population figures, 75
 World Health Organization. Please see: WHO.
 "Worse than silly," 19
 Wright, Orville: On generic obstacle to progress, 515
 Wu (Li-Jun) 1999: Mutations by alpha radn, 529

X, Y, Z

- Xanthoma: Lipid-filled lesions of skin and tendon sheath, e315, 335, e543, 351.
 Equivalent of visible atheromas, 543, 557
 Lessons from observing their behavior, 557
 Involution after favorable change of plasma lipoprotein levels, 335, 543, 557, 561, 575
 Low HDL, high Sf 0-400, 577
 X-chromosome: Inactivation of one in females, 325
 X-coefficient, e14, e63, e64, e94
 Units of y, per unit of x. Risk/rad, 499
 Demo that X-coefs reflect slope, 213, 218, 220, 221
 Xcoef/SE reflects slope's reliability, 12, 95-96
 Negative sign means a downward slope, 13, 99, 225, 507, 642
 Xrays, e517. Discovered in 1895, 9, 27, 77, 210, 212
 Cancer & IHD before 1895, 10, 209, 210, 342
 Biological impact of the xrays which never reach the film (or other image-receiver), 8
 A uniquely potent mutagen, 8, 38, 515, 532
 More mutagenic than gamma & beta radn, 9, 46-48
 Misconception: Xrays are too "weak" to hurt, 31
 Benefits of medical xrays, 9, 17, 19, 91, 234, 515
 Xrays are the agent in CT scans, fluoroscopy, mammography, 2, 5, 7, 9, 18
 Skin radiotherapy: Super-soft vs. superficial, e31
 Avg photon-energy ~ 1/3 of peak kilovoltage, 48, 522
 Orthovoltage xrays, e47, e48
 Xrays: History 1896-1960 of medical usage, 27-32.
 Pre-1960 practices contribute to 1990 MortRates, 32
 Radiotherapy tried on every chronic disease, 28, 30 (partial listing)
 Skin's response was only dose-meter for decades, 28
 Radiotherapy was routine before tonsillectomy, 28
 1937: No exam judged complete without xrays, 29, 610
 Mid-century data on xray practice, 609-616
 Who owned the xray machines in 1950? 615
 Some approximate dose-levels:
 Avg fluoroscopy exam ~ 65 Roentgens, 30, 612
 Baby's fluoro dose by age-1, sum ~ 100 R, 29, 31
 Pediatric thymus therapy, sum ~ 250 rads, 28
 Skin disorders, sum ~ 1,400 R, 30
 Ulcers, sum ~ 2000 R, 30
 Chest-xray dose was ~ 100-fold higher than now, 34
 Xrays: History 1960-1999 of medical usage, 32-38, 356
 Downward forces on avg per-capita pop'n dose, 34
 Please see next column.

Xrays: History 1960-1999 (continues):
Upward forces on avg per-capita pop'n dose, 34-37
CT scans are an upward force, 34
"Substantial increase" in fluoroscopy-use, 35
List of high-dose fluoroscopic exams, 36
Dose-measurement remains rare, 33
1989: Use of untrained xray operators, 35
X-variable. In regression analysis, e12.
In graphs, 55, 56, 63, 108
Reversal of x,y designation doesn't chg R-sq 64, 359
Y.
Y-axis: Scale varies with graph, 100, 225
Y-intercept, e95, e111
Y-variable. In regression analysis, e12, 64, 108
In graphs, 55, 63
Yamashiroya (H.M.) 1988: Viral etiology atheroscl, 307
Yeager (J. Franklin), Natl Heart Institute, 546
Yew (P.R.) 1989: Tumor hypothesis & atheroscl, 330
Yla-Herttuala (S.) 1986: Features of plaque, 303, 305
Young (S.G.) 1994: Oxidized LDL, 317
Young (Wei) 1960: Fenestra of internal elastica, 299
1963: Ingress, egress of lipoproteins from intima, 317
Zhou (Yi Fu) 1996+1997: CMVirus and restenosis, 309
ZurHausen (H.) 1998: Co-actors in cervical cancer, 164
Zweifach (B.W.), on junction between endothelial cells, 317

The guide to this index is located at page 677.

>>>>>>>>>>